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ABSTRACT 
Antigenic variation by African trypanosomes, the causative agents of animal African 
trypanosomosis, has blunted efforts to develop a vaccine candidate. Therefore, disease 
control requires surveillance, diagnosis and effective treatment schedules for the affected 
livestock. Because of ever-increasing occurrences of drug-resistance and the non-specific 
symptoms of the disease, there is a great need for the development of point of care diagnostic 
tests that are inexpensive to the end-user. One of the main bottlenecks to affordable 
serological diagnostics is the availability of highly immunogenic antigens that are sufficiently 
stable and maintain their antibody binding properties in the diagnostic tests. Parasite 
aminopeptidases and cysteine peptidases are involved in the pathogenesis of African 
trypanosomosis and therefore have high potential as antigens for the development of new 
chemotherapeutics and diagnostics. This study aimed to optimise the recombinant production 
of three known pathogenic factors namely cathepsin L-like peptidase from Trypanosoma 
vivax, TviCATL, and aminopeptidase one and two from T. congolense TcoAP1 and TcoAP2.  
For TviCATL, the full-length active site mutant construct (FLTviCATLC25A) was sub-cloned into 
pET32-a and pGEX4T-1 and subsequently used for recombinant expression optimisation 
experiments to improve target protein yield and solubility. A full-factorial design was employed 
to test varying cultivation conditions for improved soluble recombinant expression. Results 
showed that even after varying conditions, most of the recombinant FLTviCATLC25A was 
expressed in inclusion bodies. Subsequently, the sarkosyl method was employed to recover 
the protein from inclusion bodies with adequate yield. The size of the recombinant protein was 
found to be ~67 kDa and the authenticity of the expressed protein was confirmed using anti-
His6 and anti-FLTviCATlC25A antibodies. The recombinantly expressed and purified antigen 
was then used to produce polyclonal antibodies in chickens (IgY) for the detection of native 
TcoCATL within T. congolense bloodstream form cell lysate. These results demonstrate that 
this antigen has immense diagnostic potential and further development may allow for its use 
in rapid diagnostic tests. 
For the two M1 aminopeptidases of T. congolense, a different approach was used for 
recombinant expression optimisation, i.e. co-expression with molecular chaperones. This 
study showed that the molecular chaperones could help recover the misfolded and 
subsequently aggregated aminopeptidases in varying degrees when compared to expression 
without the molecular chaperones. A suitable protein-chaperone grouping was found by trial 
and error by comparing recombinant co-expression of the aminopeptidases with several 
chaperone teams namely: pGro7 (GroES-GroEL), pG-KJE8 (DnaK-DnaJ-GrpE + GroES-
GroEL), pG-Tf2 (GroES-GroEL + trigger factor), pKJE7 (DnaK-DnaJ-GrpE) and pTf16 (trigger 
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factor). In the present study, it was found that co-expression with the pKJE7 chaperone team 
could recover the most recombinant aminopeptidases from inclusion bodies and led to a two-
fold improvement in soluble recombinant production of the aminopeptidases relative to the 
sample without molecular chaperone co-expression. The pKJE7 chaperone team co-
expression experiment produced 24% soluble proportion of the total recombinant 
aminopeptidase for both TcoAP1 and TcoAP2. 
In the present study, two different approaches to recombinant soluble protein expression 
optimisation were undertaken and in the instance of molecular chaperone co-expression, a 
two-fold improvement of soluble recombinant aminopeptidases expression was achieved. In 
the case of FLTviCATLC25A, although the design of experiments approach to FLTviCATLC25A 
expression optimisation did not improve soluble expression of the protein, the use of the non-
chaotropic sarkosyl method for its resolubilisation led to much higher yields and more efficient 
downstream processing. These improvements in protein yield helps in the development of 
diagnostic tests which require adequate amounts of stable homogeneous antigen, furthermore 
these improvements can be applied in the development of an anti-disease vaccine. 
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Chapter 1:  LITERATURE REVIEW 
1.1 Trypanosomes 
Trypanosomosis was initially studied by David Bruce in 1894 while investigating the death of 
cattle in what is now known as KwaZulu-Natal in South Africa (Duggan, 1977; Brown, 2008). 
Two African Trypanosoma species are pathogenic to humans, i.e. T. b. rhodesiense and T. b. 
gambiense are human African trypanosomosis causative agents in sub-Saharan Africa. T. b. 
brucei, T. congolense, T. vivax are all also transmitted by the tsetse fly (Glossina spp.) as is 
the case for the human infective forms, and T. evansi are the main causes of animal African 
trypanosomosis in sub-Saharan Africa (Steverding, 2017). In South America T. vivax infect 
ungulates, where it is transmitted non-cyclically by hematophagous flies rather than by tsetse 
flies since the parasite is confined to the insect vector’s mouthparts (Osório et al., 2008). 
Chagas disease in South America is caused by T. cruzi, an intracellular parasite spread by 
biting flies (Duggan, 1977; Rassi and Marin-Neto, 2010). The disease surra, which is prevalent 
in Africa, South America and Asia is caused by T. evansi and is transmitted by tabanids (Brun 
et al., 1998). T. equiperdum has evolved a sexual mode of transmission and is transmitted 
during coitus in horses and causes dourine (Claes et al., 2005).  
1.1.1 Classification 
African trypanosomes are flagellated haemoprotozoan parasites belonging to the order 
Kinetoplastida, which are characterised by the presence of a rod-shaped DNA-containing 
kinetoplast at the base of the flagellum, a single flagellum attached to the body as an 
undulating membrane, and a single highly branched mitochondrion (Uilenberg, 1998). 
The species of trypanosomes infecting mammals have been divided into two groups that 
develop in different parts of the vector to the infective metacyclic stage (Enyaru et al., 2010). 
In the group Stercoraria, transmission occurs through the posterior part of the vector, while in 
Salivaria, transmission occurs through the anterior part of the vector. Also, Salivaria are the 
only trypanosomes which exhibit antigenic variation. There are at present four subgenera of 
salivarian trypanosomes, i.e. Duttonella, Nannomonas, Trypanozoon and Pycnomonas (Haag 
et al., 1998). Figure 1.1 shows the classification of trypanosomes of veterinary and medical 
importance. 
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Figure 1.1: Classification of trypanosomes of veterinary and medical importance. (Stevens et al., 
2004). 
1.1.2 Biology of African trypanosomes 
1.1.2.1 Morphology 
Trypanosomes are single-celled parasites that are elongated (ranging from 8-50 µm) and 
tapered at both ends (Figure 1.2). Since trypanosomes are eukaryotic, they contain typical 
features such as a nucleus and organelles including endoplasmic reticulum, Golgi apparatus, 
a mitochondrion and endocytosis and exocytosis systems (Bonhivers et al., 2008). 
Trypanosomes have a flagellar pocket, flagellum and mitochondrial DNA. An invagination in 
the plasma membrane protects the flagellar pocket. Due to the presence of high a 
concentration of receptors responsible for endocytosis and immune evasion, the flagellar 
pocket is considered to be a site for protein trafficking, protein and lipid sorting, and a recycling 
compartment (Gadelha et al., 2009). The flagellum which is responsible for parasite motility 
extends from the flagellar pocket. The basal body at which the flagellum is attached is called 
the flagellum attachment zone, and it also interacts with a single elongated mitochondrial DNA 
which is situated within the structure called the kinetoplast (Peña-Diaz et al., 2017). The 
mitochondrial DNA consists of a network of maxicircles (22 kb) and minicircles (1 kb). 
Maxicircles are responsible for encoding mitochondrial proteins while minicircles are 
responsible for extensive post-transcriptional modification or RNA editing of these regions 
using guide RNAs (Horn, 2014). 
3 
 
 
Figure 1.2: Anatomical features of the bloodstream forms trypomastigotes of the three most 
important animal trypanosomes. The trypomastigotes are the disease form and the target for therapy. 
(Giordani et al., 2016) 
1.1.2.2 The life cycle and distribution of African trypanosomes 
The presence of the trypanolytic factor in humans and some primate species renders them 
resistant to most trypanosomes, however T. b. rhodesiense and T. b. gambiense are 
themselves resistant to the factor and are therefore the only trypanosomes to infect humans 
(Poelvoorde et al., 2004; Baral, 2010). T. b. rhodesiense expresses the serum resistance-
associated (SRA) gene which renders it resistant to the trypanolytic factor in human sera, 
therefore, causing acute rather than chronic infections (De Greef et al., 1992; Pays, 2006). 
Trypanosomes have a dual host life cycle and therefore require special adaptations such as 
kinetoplast DNA, RNA editing, unique gene regulation, glycosomes and flagellum along with 
a flagellar pocket (Clayton et al., 1995). The parasites require the various morphological and 
gene expression changes, which are involved in the various life cycle stages, to be effectively 
coordinated (Matthews, 1999) (Figure 1.3). Mammalian infection commences with the 
acquisition of a blood meal by an infected tsetse fly where the metacyclic form of parasites 
are injected into the host bloodstream. The metacyclic form parasites transform into 
proliferative bloodstream form trypomastigotes which are entirely coated with a continuous 
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layer of variant surface glycoprotein (VSG) homodimers (Vickerman and Luckins, 1969; 
Cross, 1975). The bloodstream form trypomastigotes are long and slender in appearance 
during the ascending phase of parasitaemia. At the peak of parasitaemia, the bloodstream 
form trypomastigotes, which are now short and stumpy, are no longer proliferative (Barry and 
McCulloch, 2001; Matthews et al., 2004). The parasites then transform into insect vector 
infectious procyclic form parasites which can colonise the midgut of the insect vector and 
proliferate (McLintock et al., 1993; Redpath et al., 2000). The transformation from stumpy 
bloodstream form into procyclic form is accompanied by a change in metabolism, where ATP 
is generated by glycolysis to being generated by oxidative phosphorylation (Clayton, 1992; 
Vassella et al., 2004; Matthews, 2005). The loss of the VSG surface coat, characterises the 
parasite’s transformation into the proliferative procyclic form (Ziegelbauer and Overath, 1993; 
Gruszynski et al., 2003). 
The rapid loss of the VSG surface coat of the procyclic stumpy form requires the continued 
action of GPI-specific phospholipase C (GPI-PLC) and a surface zinc metallopeptidase (MSP-
B) (Ziegelbauer and Overath, 1993; Gruszynski et al., 2003). After the proliferation of procyclic 
form parasites within the midgut, migration towards the salivary glands occurs where they 
undergo asymmetric cell division to form stumpy and slender epimastigote form parasites (Van 
Den Abbeele et al., 1999). Only the stumpy epimastigote parasites have a brucei alanine-rich 
protein (BARP) surface coat which replaces the procyclin coat. These stumpy epimastigote 
form parasites can attach, proliferate and mature into metacyclic form parasites within the 
salivary glands of the insect vector, where they re-obtain their VSG surface coat (Tetley et al., 
1987; Urwyler et al., 2005; Urwyler et al., 2007). Once colonised, the salivary glands are the 
generation site of the metacyclic form parasites which are infectious to mammals (Sbicego et 
al., 1999). The metacyclic form parasites have a larger repertoire of VSG genes compared to 
that of the bloodstream form parasites (Barry and McCulloch, 2001). 
The bloodstream form of the T. b. brucei parasites are pleomorphic, with two different physical 
forms being present concurrently (Vickerman, 1985). The slender forms replicate by asexual 
division and are susceptible to elimination by host peptidases (Sbicego et al., 1999). The 
stumpy forms, which are non-proliferative, are resistant to elimination by host peptidases and 
can differentiate into procyclic form parasites which are then able to colonise the salivary 
glands of the insect vector (Clayton, 1992; Sbicego et al., 1999). The non-proliferative 
character of the stumpy forms acts to prevent the uncontrolled growth of the slender forms 
which would result in the rapid killing of the infected mammalian host (Matthews and Gull, 
1994). 
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Figure 1.3: Life cycle of T. brucei showing the different morphological changes that occur 
during the different stages in the vector and mammalian host. 
http://www.cell.com/trends/parasitology/fulltext/S1471-4922(16)30009-5 accessed on 16.05.2016. 
1.1.2.3 Genomic organisation 
Two genomes are present in African trypanosomes: one within the nucleus and one within the 
kinetoplast. The nuclear genome is of low complexity since 68% of the genome consists of 
single-copy sequences (Liu et al., 2005). Although most of the nuclear genome is diploid, 
areas including the VSG genes, VSG expression sites, and mini-chromosomes are not. The 
nuclear genome is approximately 3.5 x 107 bp in length, roughly the same as the genomes of 
parasites such as Plasmodium falciparum, T. cruzi and Leishmania major (Kooy et al., 1989; 
El-Sayed et al., 2000).  
1.1.2.4 Antigenic variation 
Trypanosomes have developed a process of antigenic variation to elude the host immune 
system. The outer surface of the bloodstream form trypanosomes are coated by the VSG, and 
each parasite in a population has the genetic capability of producing an antigenically distinct 
VSG (Vickerman, 1969; Taylor and Rudenko, 2006; Horn, 2014). The different VSG coats are 
termed variant antigen types (VATs). Antigenic variation is the term used to describe the 
varying expression of these VSG coats, resulting in differing populations of trypanosomes with 
a different VAT present in the blood over time. As a specific immune response develops 
against one VAT, the number of trypanosomes with that VAT decreases, the trypanosomes 
with a different VAT will survive and initiate the next wave of parasitaemia (Chung et al., 2004). 
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The expression of different VSG coats is thought to occur when a VSG gene, often located in 
a non-transcribed region, is duplicated into a transcriptionally active region (Barry and 
Carrington, 2004). 
1.2 African trypanosomosis 
In 2015, 2804 cases of HAT were reported to the WHO, with gambiense HAT comprising the 
bulk of cases (2733, a 90% reduction since 1999) and 71 cases were rhodesiense HAT (89% 
reduction). This includes cases diagnosed in both endemic and non-endemic countries 
(Büscher et al., 2017). The number of cases reported does not reflect the true number of cases 
due to the limitation of diagnostic methods and the rural setting of disease incidence. The 
disease was estimated to have a health burden of approximately 1.6 million disability-adjusted 
life years (DALYS) in 2004 (Fevre et al., 2008) which has a negative effect on economic 
development in central Africa. The impact of AT in Africa results in excess of $4.5 billion in 
annual economic losses. 
The disease affects mostly poverty-stricken communities living in remote rural areas of Africa 
and tends to be fatal if not treated. The geographic distribution of the foci of the disease is 
synonymous with the tsetse fly belt which stretches from north of the Kalahari desert to the 
south of the Sahara (Barrett et al., 2003). Within this region, it is estimated that 42-62 million 
head of cattle and other domestic animals are at risk of animal African trypanosomosis (AAT) 
(Swallow, 2000). 
Tsetse flies are distributed in approximately 10 billion km2 of Africa (Figure 1.4, B) (Mattioli et 
al., 2004). The Palpalis group of the tsetse fly are the insect vector for the human infective 
trypanosomes, whilst for the animal infective parasites it’s the Morsitans group (Hargrove et 
al., 2003) (Figure 1.4, A). Human infections by T. b. gambiense is known to occur in 24 
countries across the west and central regions of Africa (Simarro et al., 2008; Simarro et al., 
2012). This species is responsible for over 90% of reported HAT infections with the remainder 
of infections being caused by the T. b. rhodesiense species in east and southern Africa 
(Simarro et al., 2008; Simarro et al., 2011) (Figure. 1.4, A). The former causes chronic 
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infection, where death can occur within years while the latter causes acute infection with death 
occurring within months (Holt et al., 2016). 
 Figure 1.4: Distribution of tsetse flies in Africa and its effect on human and cattle population. 
(A) Map showing human African trypanosomosis cases, parasite species and tsetse fly distribution 
(Wertheim et al., 2012). (B) Map Showing distribution of tsetse fly and cattle in Africa (IAEA, 2009).  
Trypanosome infections in livestock are 100 to 150 times more likely to occur when compared 
to human infections (Alsan, 2015). Infections brought about by the T. b. brucei species are 
characterised by the onset of necrosis, oedema and numerous inflammatory disease 
symptoms (Eisler et al., 2004). Infections by the T. congolense and T. vivax species cause 
extra-vascular haemolytic anaemia in infected cattle and is responsible for the development 
of chronic anaemia and results in decreased productivity and losses of livestock (Eisler et al., 
B 
A 
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2004). N’dama cattle (Bos taurus) are able to limit parasitaemia, and the disease symptoms 
caused by T. congolense infection and are thus described as trypanotolerant (Authié, 1994), 
whereas African Zebu cattle (Bos indicus) are susceptible to the disease (Authié, 1994). 
1.2.1 Pathogenesis 
Pathogenic trypanosomes are responsible for three known pathological states in African 
livestock, which have been given the common names nagana (bovine trypanosomosis), surra 
(T. evansi infections) and dourine (T. equiperdum) (Table 1.1). Bovine trypanosomosis is 
caused mainly by the Salivarian group of African trypanosomes (Stevens et al., 2004) (Table 
2.1). 
Table 1.1 Overview of the pathogenic salivarian trypanosomes. (Gibson, 2007). 
Subgenre Species Disease Distribution 
Potential 
mammalian 
hosts 
Trypanozoon 
T. brucei brucei Nagana 
Tropical 
Africa 
Wild and 
domestic 
animals 
T. brucei 
rhodesiense 
Rhodesian 
sleeping 
sickness 
East Africa 
Humans, wild 
and domestic 
animals 
T. brucei gambiense 
Gambian 
sleeping 
sickness 
West and 
Central 
Africa 
T. evansi Surra 
North Africa, 
Middle East, 
Asia, South 
America 
Wild and 
domestic 
animals 
T. equiperdum Dourine Equines 
Nannomonas 
T. congolense Nagana 
Tropical 
Africa 
Wild and 
domestic 
animals T. simiae 
Acute porcine 
trypanosomosis 
Tropical 
Africa, 
South 
America 
Duttonella T. vivax Nagana 
Tropical 
Africa 
Wild and 
domestic 
animals 
Pycnomonas T. suis 
Porcine 
trypanosomosis 
Tropical 
Africa 
Suids 
 
These pathogenic trypanosomes can be separated into haematic trypanosomes, which 
include T. congolense and T. vivax, and humoral trypanosomes, which include T. b. brucei, T. 
b. rhodesiense and T. b. gambiense. Haematic trypanosomes are limited to the blood vessels 
of the host animal while humoral trypanosomes are present in plasma, intracellular tissues, 
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lymphatic system and are able to cross the blood-brain barrier (Uilenberg, 1998; Lonsdale-
Eccles and Grab, 2002). Although T. b. brucei is capable of tissue invasion, it is generally less 
pathogenic than T. congolense and T. vivax. Anaemia is a symptom typical of both groups 
while infection by humoral trypanosomes may result in necrosis and inflammation (Losos and 
Ikede, 1970; Gibson, 2007). 
The progress of AAT is dependent on the animal host, trypanosome species and strain. 
However, several clinical signs of the disease are shared between most domestic animals 
irrespective of the species of trypanosomes involved. Detection of parasitaemia and anaemia 
occur between 1-3 weeks after infection depending on the pathogenesis and infective dose of 
the trypanosome strain, and immune status of the host animal. The initial chancre is caused 
by the rapid multiplication of trypanosomes in the skin and the area surrounding the tsetse 
bite which results in the enlargement of the lymph nodes (Mattioli et al., 1999). Once in the 
lymphatic system, the parasites have access to the host bloodstream and progress to the 
blood filtering organs such as the spleen and liver (Taylor and Authié, 2004). 
Initial clinical signs of the acute phase of AAT include enlarged lymph nodes and spleen, 
weakness, lethargy, general loss of condition, reduced milk production and abortion. Infection 
with T. congolense, T. vivax or T. b. brucei may also result in damage to the bone marrow, 
heart, endocrine glands, and reproductive glands and in the case of T. vivax, the central 
nervous system. Death may occur in the first few weeks, or the animal may stabilise and begin 
a slow recovery. Animals are most likely to progress to the chronic phase of the disease 
characterised by intermittent parasitaemia, stunted growth, wasting and infertility (Bengaly et 
al., 2002). Chronic trypanosomosis usually results in death by congestive heart failure (a result 
of prolonged anaemia), myocardial damage and increased vascular permeability (Taylor and 
Authié, 2004). 
1.2.2 Control strategies  
A multi-faceted approach was adopted for the control of African trypanosomosis in animal and 
human populations. Vector control and the use of trypanocides are the historical control 
measures for bovine and other animal forms of African trypanosomosis (Van den Bossche, 
2001; Baral, 2010). Vector control strategies include chemical control through the use of 
insecticides (Allsopp, 1984), the use of fly baits, traps and the adoption of the sterile insect 
technique (Vreysen et al., 2000). For controlled cattle grazing areas, vector control can also 
be achieved by the expansive clearing of vegetation which sustains tsetse populations. 
Insecticide-treated cattle are protected from tsetse bites, and tsetse populations are also 
reduced due to the death of flies that take blood meals from insecticide-treated cattle. In T. b. 
rhodesiense endemic areas, where cattle serve as reservoirs for the disease in the absence 
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of wild animals, treatment of cattle with insecticides, could also help control the human 
disease. Vector control gets more costly upon scale-up and may not be sustainable, therefore, 
the use of trypanocides became the main control strategy in many rural and poor endemic 
areas (Chitanga et al., 2011). Chemoprophylactic and chemotherapeutic control of the disease 
has two important effects namely, eliminating the reservoir of transmissible trypanosomes and 
reducing deaths caused by infection (Fevre et al., 2008). Depending on the severity of 
symptoms exhibited, using trypanocide treatment in the chronic phase may take much longer 
for clinical recovery than effective treatment at the acute phase of the disease which usually 
leads to a prompt recovery (Giordani et al., 2016). A few African cattle breeds such as 
Dahomey, N’Dama and Muturu developed resistance against trypanosome infection. This is 
known as trypanotolerance and is the ability to survive and be productive even when infected 
(Authié, 1994). Trypanotolerance allows the cattle to limit parasitaemia and anaemia enabling 
these animals to cope with infections. Raising trypanotolerant breeds is often seen as an 
important control strategy and has improved livestock productivity in multiple endemic areas 
(Naessens, 2006). 
Treatment and prophylaxis of AAT relies mainly on five trypanocides (Table 1.2), most being 
actively used for the past 50 years (Munday et al., 2015). Furthermore, several factors limit 
their usage, such as the trypanocides causing local irritation at the injection site and more 
importantly, past widespread usage has led to ever increasing trypanocide resistance, and 
their similarity in composition has promoted cross-resistance (Delespaux and de Koning, 
2007; Giordani et al., 2016). Many of the popular trypanocides have been shown to act against 
the parasite’s kinetoplast causing the protozoan’s death (Wilkinson and Kelly, 2009), however 
the actual biochemical mechanisms of action and resistance are yet to be elucidated. The 
different trypanocides have differing therapeutic effectiveness based on the pharmacokinetics 
that affect distribution and the specific potency against each trypanosome species which in 
turn have different biochemical physiology and host organ distribution between them (Giordani 
et al., 2016).  
The available trypanocides are mostly therapeutic while some are prophylactic (Stevenson et 
al., 1995). The decision to administer prophylactic or therapeutic drugs is based on some 
observations such as drug availability and risk of infection (Diall et al., 2017). In areas of high 
infection prevalence, prophylactic drugs should be applied across the whole herd as this 
approach will be more cost-effective, avoiding the loss of revenue associated with infections 
and significant reduction in morbidity and mortality, whereas therapeutic drugs are more 
suitable for low prevalence areas where infections of the affected animals have been 
confirmed (Gu et al., 1999). Prophylactic and therapeutic drugs that are administered at single 
doses are preferred when compared to multi-dose regimens since this is not workable in 
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developing countries where animal care facilities are few and far between (Giordani et al., 
2016). As new trypanocides are unlikely to become available in the foreseeable future 
(optimistically it will take at least five years for the next most promising drug to go into market), 
efficient use of those already in market is paramount (Giordani et al., 2016). However, 
trypanocide use in the field is hard to monitor let alone regulate. In high prevalence African 
countries, trypanocide administration is usually performed directly by farmers, that can buy 
them for less than US$ 1 per treatment (Giordani et al., 2016). Unfortunately, most farmers 
have little access to facilities that provide information regarding proper trypanocide usage and 
dosage and tools that allow for accurate diagnosis; usually farmers depend only on clinical 
symptoms that are not disease-specific, hence these factors lead to trypanocide misuse 
(Grace et al., 2009). Furthermore, an unregulated market leads to the widespread use of poor 
quality or counterfeit trypanocides especially in Africa where documented product 
specifications are scarce (Tchamdja et al., 2016). Two laboratories were established, one in 
Der Es Salaam and one in Dakar, under the watch of GALVmed-FAO (Global Alliance for 
Livestock Veterinary Medicines; Food and Agriculture Organization of the United Nations) to 
improve the standards of trypanocides and their usage (Sutcliffe et al., 2014).  
Vaccination is a viable alternative to chemotherapy in the control of African trypanosomosis. 
However, there are currently no vaccines available against trypanosomosis (Agbo et al., 
2003). Vaccine development has been challenging due to antigenic variation by the parasites 
(Lipsitch and O'Hagan, 2007). Consequently, a new vaccine approach involving the use of 
DNA vaccines is being explored. DNA vaccines have been shown to be successful in inducing 
immune protection against many protozoan-caused diseases (Handman et al., 2000; Laddy 
and Weiner, 2006). Due to the limitations in anti-parasite vaccinations, it was necessary to 
introduce an alternative approach to vaccination. The anti-disease vaccine approach was thus 
developed, in which efforts are directed to targeting pathogenic factors rather than the parasite 
itself (Authié et al., 2001). This approach led to the targeting of several peptidases, which play 
a role in the parasites’ pathogenesis. Infections of trypanotolerant cattle with T. congolense 
resulted in an increased IgG response against TcoCATL antigen. The levels of anti-TcoCATL 
antibodies were directly proportional to levels of resistance in trypanotolerant cattle and 
correlated with a decrease in anaemia in cattle (Authié et al., 2001). 
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Table 1.2: Currently available trypanocides (Giordani et al., 2016). 
Name Trade namea Structure Indication 
Diminazene aceturate Berenil 
 
T. vivax and T. congolense but less 
potent on T. evansi and T. b. brucei 
infections 
Homidium bromide 
Homidium chloride 
Ethidium novidium 
 
 
T. congolense and T. vivax but less 
potent against T. b. brucei 
Isometamidium chloride Trypamidium 
 
T. vivax and T. congolense but less 
potent against T. b. brucei 
Quinapyramine sulphate 
Quinapyramine sulphate:chloride 
(3:2 w/w) 
Antrycide 
 
T. congolense, T. vivax, T. evansi, 
T. b. brucei, T. equiperdum and T. 
simiae  
Suramin sodium Naganol 
 
T. equiperdum, T. b. brucei and T. 
evansi 
a Trade name list is not complete 
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1.2.3 Diagnosis 
Successful control of trypanosomosis depends on reliable detection of the parasites, which is 
difficult in closely related sub-species (Agbo et al., 2003). Point of care diagnostics is widely 
mooted as one of the best tools to combat AAT. Ideally, any point of care diagnostics up for 
consideration should meet the ASSURED criteria that is: it should be affordable, sensitive, 
specific, user-friendly, rapid, equipment-free and deliverable to end-users (Wild, 2013). T. 
vivax, T. congolense and T. brucei infection exhibit similar clinical symptoms. Therefore 
diagnosis of trypanosomosis cannot be reliably based only on clinical signs, but require 
laboratory tests (Holmes, 2013). Diagnosis in the laboratory is achieved through 
parasitological, molecular and serological techniques. 
1.2.3.1 Parasitological diagnostics 
Parasitological diagnosis aims at detection and identification of trypanosome parasites in the 
infected host blood circulation. Motile trypanosomes can be identified in thick or thin smears 
of blood on a microscope slide and through light microscopy. Experts are able to distinguish 
T. congolense and T. vivax based on their morphology but the sensitivity of the technique is 
not sufficient (Nantulya and Lindqvist, 1989). Introduction of haematocrit centrifugation, which 
concentrates the parasites in the buffy coat layer allowing simple detection of trypanosomes 
by light microscopy, improved the sensitivity of the method (Ancelle et al., 1996; Matovu et al., 
2012). Blood parasite levels as low as 5 x 103 T. brucei, 2.5 x 102 T. congolense and 5 x 102 
T. vivax parasites per ml of blood can be detected using this method (Paris et al., 1982). 
However, this technique depends on the availability of electricity, therefore, cannot readily be 
used in the field. Due to lower sensitivity and failure to detect parasites at earlier stages of 
infection, the development of alternative diagnostic methods such as molecular and 
serological diagnosis was necessary. 
1.2.3.2 Molecular diagnostics 
Effective identification of low-level parasite copy numbers was enhanced by the introduction 
of the polymerase chain reaction (PCR) that uses oligonucleotide primers that are highly 
specific for the detection of trypanosome DNA (Moser et al., 1989). Since the use of several 
specific primers for PCR is time-consuming, a single molecular marker to identify several 
trypanosomes was attempted, namely the advanced single PCR utilised multi-copy internal 
transcribed spacer 1 (ITS1) within ribosomal RNA genes of trypanosomes. This method could 
distinguish a pool of trypanosomes in a single PCR run since each species of trypanosome 
contains unique sized ITS1 compared to other species. Thus the PCR product of each species 
migrates at a specific size (Desquesnes et al., 2001). This method is preferable for diagnosis 
of trypanosomosis since it is associated with improved species-specific assays but it requires 
substantially more complicated equipment and experienced personnel to conduct the test. 
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Although this method still shows low sensitivity for detection of T. vivax (Desquesnes et al., 
2001), a study conducted by Fikru and colleagues (2012), reported a five-fold higher detection 
efficiency for T. vivax as compared to the haematocrit centrifugation technique. The ITS1 PCR 
assay in a “touchdown” format was identified as a good diagnostic technique for evaluating 
drug efficacy against T. congolense infection in cattle (Tran et al., 2014). Sequences from 
genes encoding for TviCATL from African and South American isolates were previously 
evaluated as suitable genetic markers. The use of these genetic markers for diagnosis showed 
immense potential as it used regions in the CATL coding sequences shared by all T. vivax 
genotypes but not those found in other trypanosomes making them perfect for a species-
specific and sensitive PCR diagnostic assay (Cortez et al., 2009). 
PCR-ELISA, which couples PCR for a specific species to ELISA was developed. In PCR-
ELISA, nested PCR using specific primers is used for the amplification of DNA, after which 
the specificity of the PCR products is assessed by coating PCR products on ELISA plates. 
PCR-ELISA has been effective for the detection of T. vivax and T. brucei but not T. congolense 
in the peripheral blood of infected cattle. This technique is limited by its high cost, preventing 
its use in poorly resourced laboratories in African countries (Masake et al., 2002; Cabrera et 
al., 2009). 
An alternative to PCR-based diagnostic techniques, the loop-mediated isothermal 
amplification (LAMP) method has been introduced (Kuboki et al., 2003). Although it is an 
expensive procedure, the LAMP technique amplifies parasite DNA with relatively high 
specificity, reproducibility and efficiency as compared to PCR-based techniques. Although this 
method has been used for the diagnosis of T. congolense infections in livestock, this method 
has mainly been used for the diagnosis of human-infecting T. brucei parasites (Mitashi et al., 
2012). 
1.2.3.3 Serological diagnostics 
Serological diagnosis is a suite of immunodiagnostic techniques that involve antigen or 
antibody detection (Luckins, 1977; Nantulya and Lindqvist, 1989). Since trypanosome lysis 
relies on both complement and antibody, complement fixation tests (CFT) could be used for 
trypanosomosis diagnosis (Nantulya and Lindqvist, 1989). In the early stages of AAT 
serodiagnostics immunofluorescence assays (IFA) were the principal method for diagnosis 
and was shown to be sensitive, specific but not species-specific (Luckins, 1977). Serum or 
blood impregnated filter paper eluates can be used for IFA. Blood from mice infected with 
either T. b. brucei or T. b. gambiense is used as the antigen for IFA (WHO, 1998). The assay, 
however, is not quantitative, requires complicated equipment and the lack of a standardised 
antigen makes it a poor choice for active case finding in the field. Mass population screening 
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for the diagnosis of T.b. gambiense has advanced by the introduction of the card agglutination 
test (CATT)/T. b. gambiense (Büscher, 2014) (Figure. 1.5). The CATT agglutination assay is 
fast, simple and is useful for the diagnosis of T. b. gambiense infected patients by its ablity to 
detect in sera or blood plasma, T. b. gambiense-specific antibodies (Magnus et al., 1978; 
Büscher, 2014). The lysed T.b. gambiense bloodstream form parasites of the LiTat 1.3 VAT 
are used as the CATT antigen. Infections with trypanosome strains that lack the LiTat 1.3 gene 
may lead to false negative CATT results (Dukes et al., 1992; Enyaru et al., 1998). The 
efficiency of CATT relies on optimal fixing and stabilisation of the parasite using formaldehyde 
in order to detect the whole trypanosomes in the agglutination test (Nantulya and Lindqvist, 
1989). 
 
Figure 1.5: A card agglutination test example using a 1:4 dilution of blood samples. Sample 1 to 
3 exhibit a strong positive reaction. Sample 4 exhibits a weak positive reaction while the remaining 
samples are negative for trypanosomal infection (Chappuis et al., 2005). 
The development of ELISA was a breakthrough since it can be used for large-scale testing. 
The major drawback of ELISA is that until recently the source of antigen for the test was either 
whole parasites or crude parasite lysate. ELISA was found to be a suitable diagnostic tool for 
the detection of bovine anti-trypanosome antibodies using both bloodstream form and 
procyclic trypanosomes (Greiner et al., 1997). When antigen-capture ELISAs were used for 
diagnosis of T. vivax and T. congolense in experimentally infected cattle, the overall specificity 
was high while the sensitivity was very low (Eisler et al., 1998). Due to the lower sensitivity of 
direct ELISA, immunoassay methods for the detection of bovine anti- T. congolense and anti-
T. vivax antibodies were developed. This assay with improved sensitivity and specificity uses 
specific ELISA kits, I-TAB ELISA-(TcAGd) and –(TvAGd) where plates were precoated with 
denatured antigen (AGd) from T. congolense (TcAGd) and T. vivax (TvAGd), respectively. 
Antigens used in this indirect ELISA were detergent-denatured lysates from bloodstream T. 
congolense and epimastigote T. vivax parasites cultured in vitro (Rebeski et al., 2000; Lejon 
et al., 2003). The use of whole parasite lysates as a source of antigen is a major limitation to 
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these techniques because it is difficult to standardise the preparation of trypanosome lysates. 
These lysates are prepared in different ways either from parasites propagated in rodents or 
grown in culture using different protocols. Additionally growing T. vivax in culture is particularly 
difficult (Boulangé et al., 2017). 
Standardised recombinant expression systems were used to produce antigens with diagnostic 
potential to avoid the use of whole parasites as antigens that are cultured in vitro or propagated 
in vivo. Targeting non-variant trypanosomal macromolecules, which are highly antigenic for 
example hsp70, showed improved specificity in serodiagnosis (Bannai et al., 2003; Bossard 
et al., 2010). The immunodominant antigen hsp70 that is closely related to mammalian 
immunoglobulin binding protein (BiP), is expressed in all lifecycle stages of T. congolense, T. 
vivax and T. brucei (Boulangé and Authié, 1994). In an inhibition ELISA format, recombinant 
hsp70/BiP was used as an antigen for antibody detection in sera from cattle with natural or 
experimental T. congolense infections. The secondary infections were detected at higher 
sensitivity than primary infections (Boulangé and Authié, 1994; Boulangé et al., 2002; Bossard 
et al., 2010). A proteomic approach was used for identifying trypanosomal antigens with 
diagnostic potential (Sullivan et al., 2013). A flagellar-associated protein, TvGM6 was 
heterologously produced in an E. coli expression system and used for the detection of 
antibodies in sera from cattle with T. vivax infections via indirect ELISA (Pillay, Izotte, et al., 
2013). The protein TvY486_0045500 and TvY486_0019690 are invariant surface 
glycoproteins with diagnostic potential. These antigens were heterologously produced in E. 
coli and used in an indirect ELISA for the detection of T. vivax infections. High sensitivity and 
specificity were reported (Fleming et al., 2014). When parasites are lysed, pathogenic factors 
such as cysteine peptidases are released within the host bloodstream, and these peptidases 
have diagnostic potential. The cathepsin-B of T. congolense TcoCB1  and the GM6 antigen of 
T. vivax TviGM6 are examples of pathogenic factors with diagnostic potential (Boulangé et al., 
2017). 
Immunodiagnostic tests based on trypanosomal antigens, either detect the antibodies 
produced in the infected host or the antigen released into the bloodstream following parasite 
lysis. Both antibody (inhibition ELISA) and antigen detection require specific antibodies 
produced in experimental animals. To produce polyclonal antibodies, egg yolk immunoglobulin 
(IgY) technology represents a preferred method that offers advantages with respect to animal 
care, cost and antibody yield.  Due to the phylogenetic distance between chickens and 
parasites, parasite antigens are highly immunogenic in chickens and antibody production in 
hens is readily stimulated. Recombinant trypanosomal antigens such as structural proteins; 
ISG65 and ISG75, and proteolytic enzymes; oligopeptidase B, pyroglutamyl peptidase and 
the cysteine peptidase TcoCATL from T. congolense, have been reported to be very 
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immunogenic in chickens as evidenced by antibodies with high signals in ELISA (Eyssen, 
2014). The chicken anti-trypanosomal antibodies produced in the study conducted by Eyssen 
(2014) were used for diagnosis of AAT using an antibody detection inhibition ELISA format as 
well as an indirect antibody detection ELISA. An alternative way of producing antigen detection 
reagents for use in immunodiagnostics is through identification of single chain variable 
fragments (scFv) of antibodies that recognise the diagnostic antigen of interest. Phage display 
technology is used to this end (Barbas, 2001).  
Several components of an antigen ELISA can be packaged into a convenient, rapid diagnostic 
test (RDT) that in turn uses the process of chromatography that is especially suited to simple 
and rapid diagnosis (Figure 1.6) (Nguyen et al., 2014).  
 
Figure 1.6: Example of a rapid diagnostic test for point-of-care use. (A) Blood serum from an 
uninfected cow. No signal on Tv indicator and Tc indicator, but valid because of control line validation. 
(B) Blood serum from T. theilieria infected cow. No signal Tv indicator and Tc indicator (C) Blood serum 
from a T. congolense-infected cow. The positive signal on Tc line and no for Tv line. (D) Blood serum 
from T. vivax-infected cow. A positive signal from Tv indicator and no Tc indicator. (E) Blood serum 
from a cow with a mixed-infection of T. congolense and T. vivax. Positive on both Tc and Tv indicators. 
(Boulangé et al., 2017). 
The RDT is made-up of a lateral test flow strip encased within a plastic cassette. The strip 
itself is made-up of several components namely, a polyester conjugate pad, a whole blood 
separator sample pad, a nitrocellulose membrane and a paper adsorbent pad. In terms of the 
RDT shown in Figure 1.6, the recombinant antigens TviGM6 (Tv test line, 1.2 mg/ml) and 
TcoCB1 (Tc test line 0.65 mg/ml) and polyclonal anti-rabbit goat IgG (control line) were coated 
onto the nitrocellulose membrane. The gold conjugate used for detection was manufactured 
by adsorbing the recombinant antigens TviGM6 and TcoCB1 together with the rabbit IgG onto 
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gold nanoparticles. The nanoparticles were then coated onto the conjugate pad part of the 
lateral flow strip. This design allows for the testing of either blood or serum samples (Boulangé 
et al., 2017). A test sample can then be applied to the RDT sample well with a drop of PBS 
buffer. The result develops within 10 min of incubation, if only the control line is made visible 
while the other test lines remain unchanged then the result is negative. If a line appeared for 
either the Tc (TcoCB1) or Tv (TviGM6) region in addition to the test line then the result was 
positive. If the control line wasn’t visible after a test, then the test was invalid (Boulangé et al., 
2017). 
1.3 Peptidases 
Peptidases are enzymes that cleave peptide bonds in polypeptides (Barrett et al., 2012) and 
either have amino or carboxy peptidase  or endopeptidase activity (McKerrow et al., 2006). 
Seven classes of peptidases have been discovered namely metallo, cysteine, aspartic, serine, 
threonine, glutamate and asparagine catalytic types (Barrett et al., 2012). The clans, within 
these classes, usually have similar tertiary structures based on their evolutionary relationships 
(Caffrey and Steverding, 2009). 
1.3.1 Cysteine Peptidases 
1.3.1.1 Classification of cysteine peptidases 
Cysteine peptidases are classified into clans, which are then differentiated into families based 
on sequence similarity, possession of inserted peptide loops and biochemical specificity to 
peptide substrates (Rawlings et al., 2009). Cysteine peptidases contain a thiol group on the 
catalytic cysteine residue which is usually deprotonated by the histidine side-chain. The 
anionic sulfur atom is then capable of a nucleophilic attack on the carbonyl carbon of the 
peptide bond, forming a tetrahedral intermediate. The tetrahedral intermediate then undergoes 
acylation forming an enzyme-substrate thiol ester and releasing the C-terminal portion of the 
substrate. The enzyme-substrate thiol-ester is hydrolysed by water to form a second 
tetrahedral intermediate which undergoes deacylation releasing the N-terminal part of the 
substrate from the enzyme (Figure 1.7) (Rawlings et al., 2009). 
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Figure 1.7: Proposed reaction mechanism for papain-like cysteine peptidases. These peptidases 
contain a nucleophilic cysteine thiol in their catalytic triad  (Lecaille et al., 2002). 
Clan CA is characterised by a catalytic triad containing Cys25, His159 and Asn175 (papain 
numbering) (Barrett et al., 2012). All clan CA peptidases are inhibited by trans-epoxysuccinyl-
L-leucyl-amido (4-guanidino) butane (E-64) and have a substrate specificity determined by the 
S2 pocket (Barrett and Kirschke, 1981; Barrett et al., 1982). Clan CA peptidases are either 
targeted to intracellular vesicular compartments or are secreted (Barrett and Kirschke, 1981). 
Family C1 of Clan CA contains papain family cysteine peptidases, including mammalian 
cathepsins B and L, and parasite peptidases: falcipains from P. falciparum, cysteine peptidase 
A, cysteine peptidase B and cysteine peptidase C from Leishmania mexicana, TcoCATL from 
T. congolense and TviCATL from T. vivax as well as TcrCATL from T. cruzi (Authié et al., 
1992; Cazzulo et al., 2001; Grams et al., 2001; Zadeh-Vakili et al., 2004; Kumar et al., 2007; 
Beckham et al., 2009; Rawlings et al., 2009). Family C2 of Clan CA contain the calpain-like 
cysteine peptidases which are calcium-dependent cytosolic cysteine peptidases which lack a 
signal sequence but possess a calcium binding domain (McKerrow et al., 2006). 
1.3.1.2 Cathepsin L-like cysteine peptidases 
Cathepsin L-like peptidases (CATL) have structural features similar to most papain-like 
peptidases (Barrett et al., 2012). The structure of CATL peptidases, including TcrCATL and 
TcoCATL homologues fold into two domains, an α-helical L-domain and an R-domain rich in 
antiparallel sheets forming a β-barrel-like motif (Figure 1.8, A) (Lecaille, Cotton, et al., 2001).  
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Figure 1.8: Illustrations of TcrCATL interaction with an inhibitor. (A) Amino acid side-chains 
involved in binding are highlighted in magenta. Hydrogen bonds are indicated by dashed lines (Choe 
et al., 2005). (B) Schematic representation of the CATL peptidase from N to C terminus. The catalytic 
domain is flanked by the pro-region and the C-terminal domain, thus forming a zymogen (Hoelz et al., 
2016). 
CATL peptidases are synthesised as inactive zymogens containing the pro-region of the pro-
peptide (Figure 1.8, B). The zymogen is activated to the mature peptidase by cleavage of the 
pro-peptide in the acidic milieu of the endosome. The synthesis of cysteine peptidases as 
inactive precursors has many benefits. These include pro-regions acting as intramolecular 
chaperones to enhance protein folding, regulate peptidase activity by blocking the active site, 
and as a signal that directs peptidases to appropriate intracellular compartments (Lalmanach 
et al., 1998). The propeptide contains a highly conserved helical ERFNIN motif found in all 
cathepsin L-like cysteine peptidases. This motif is thought to be crucial for trafficking into 
lysosomes and maturation of cysteine peptidases (Karrer et al., 1993). The trypanosomal 
cysteine peptidases such as TcrCATL and TcoCATL contain a C-terminal extension which is 
not present in mammalian CATL peptidases (Åslund et al., 1991; Rosenthal, 1999). The C-
terminal extension of TcoCATL is linked to a catalytic domain by a proline-rich hinge region 
while that of TcrCATL is linked by a threonine-rich hinge region (Lalmanach et al., 1998). The 
presence of the C-terminal extension in most trypanosomal CATLs confers relatively high 
antigenicity and immunogenicity (Cazzulo and Frasch, 1992). The C-terminal extension of 
plant cysteine peptidases was shown to play a fundamental role in zymogen activation, 
catalytic activity, folding and stability of the peptidase (Dutta et al., 2011). 
A 
B 
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The substrate specifically binds to the active site cleft which contains subsites (S) each limited 
to bind only one specific amino acid residue of the peptide substrate (P). The peptidase active 
N-terminal (…S3-S2-S1) and primed C-terminal subsites (S1’, S2’, S3’) is complementary to 
peptide substrate amino acid residues (…P3-P2-P1) and primed peptide substrate residues 
(P1’, P2’, P3’), respectively (Figure 1.9) (Schechter and Berger, 1967). The P2 residue which is 
complementary to the active site S2 pocket exhibits a very pronounced interaction with both L 
and R domains of cathepsins (Sajid and McKerrow, 2002; Turk et al., 2012). Therefore, the 
substrate specificity of most papain-like peptidases is determined by the S2 pocket. The 
trypanosomal peptidases including TcrCATL and TcoCATL prefer bulky hydrophobic amino 
acids such as phenylalanine in P2 (Eakin et al., 1992; Elaine et al., 1997; Pillay et al., 2010). 
TcrCATL exhibits a dual specificity for both basic (Arg) and hydrophobic residues (Phe) at the 
P2 position. This is attributed to the presence of Glu205 at S2 of TcrCATL which is responsible 
for adjusting the conformation of the S2 pocket in such a way that it is flexible to accommodate 
both hydrophobic and basic residues (Gillmor et al., 1997). Conversely, TcoCATL exhibits 
restricted specificity for Phe residues at P2. This is because, at the bottom of the S2 pocket of 
TcoCATL, there is Leu205 instead of Glu205, which restricts the binding capacity of the S2 pocket 
(Chagas et al., 1997; Gillmor et al., 1997). It has also been reported that the presence of 
conformationally constrained substrate analogues results in incorrect binding into the S2 
subsite of TcoCATL and this suggests that the hydrophobic Phe group is crucial for efficient 
binding and hydrolysis of the substrate (Lecaille, Authié, et al., 2001). 
 
Figure 1.9: The Schechter and Berger schematic representation of the interaction of the peptide 
substrate with the active site of cysteine peptidase. Peptide (P) substrate with its N- and C-terminus 
indicated, interacts with peptidase sub-sites (S). The peptidase substrates are complementary to the 
sub-sites of the peptidases, and this allows correct sub-site fitting. The residue in the P2 position is 
strictly bulky hydrophobic in the case TcrCATL. Sulfhydryl (SH) of the active site cysteine attacks the 
peptide bond during hydrolysis. http://www.nature.com/horizon/proteases/ 
background/figs/prespective_f1.html (Accessed 27 October 2016). 
The cathepsin L-like peptidases TbbCATL (Mackey et al., 2004), TcoCATL (Lalmanach et al., 
2002) and TbrCATL (Kerr et al., 2010) are expressed throughout each of the parasites’ four 
life cycle stages, but most significantly in the bloodstream form stage where it is localised in 
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the lysosomes (Mbawa et al., 1991; Scory et al., 1999; Caffrey et al., 2001). The antigens 
used for serodiagnosis need to be expressed in the bloodstream form, and therefore the CATL 
antigens are potential diagnostic antigens. 
Many isoforms of TcoCATL exist (Pillay et al., 2010) and several isoforms are also observed 
in the CATL peptidases from L. mexicana and T. cruzi (Mottram et al., 1997; Lima et al., 2001). 
TcrCATL is the major CATL lysosomal peptidase present in the T. cruzi parasite and is 
involved in the invasion process of host smooth muscle and epithelial cells (Aparicio et al., 
2004; Yoshida, 2006). It was suggested that TcrCATL might be involved in immune system 
evasion by digesting the hinge region of human IgG subclasses (Berasain et al., 2003). It was 
further suggested that TcrCATL, TcrOPB and metacyclic surface glycoprotein (gp82) play a 
vital role in the mobilisation of Ca2+ from intracellular stores, leading to host cell invasion by T. 
cruzi parasites (Burleigh et al., 1997; Caler et al., 1998).  
The 3D structures of only two kinetoplastid CATLs have been solved to date in the presence 
of different substrates and inhibitors, namely those from T. cruzi and T. b. rhodesiense (Figure 
1.10). 
 
Figure 1.10: The structures of TcrCATL, TbrCATL and PfCATL3. Ribbon representation and 
superimposition of TcrCATL (pink), TbrCATL (aquamarine) and PfCATL3 (yellow) are shown. Insertions 
in PfCATL3 are coloured purple (Kerr et al., 2010). 
 The Tropical Disease Research (TDR) targets database (http://tdrtargets.org/) lists TcrCATL 
and TbrCATL as druggable targets, and these peptidases are also thought to be potential 
diagnostic antigens (Boulangé et al., 2017). TbrCATL, the CATL from T. b. rhodesiense was 
thought to have diagnostic potential due to the fact that TcrCATL was a diagnostic antigen 
and that it was highly expressed in bloodstream form parasites but was not recognised in 
infected human sera (Manful et al., 2010). 
TviCATL, (CCD21670.1), TcoCATL, (CAA81061.1) and TcrCATL (P25779.1) share a 78%, 
72% and 71% sequence identity to TbrCATL, (CAC67416.1) respectively (Figure 1.11) and 
thus should possess similar diagnostic and chemotherapeutic potential. 
23 
 
 Figure 1.11: Sequence alignment of the cathepsin-L like peptidases from T. congolense, T. b. 
rhodesiense, T. vivax and T. cruzi. Multiple sequence alignment of the CA clan, C1 family of cysteine 
peptidases generated using ClustalΩ (Sievers et al., 2011). Protein sequences were obtained from 
UniProtKB (http://www.uniprot.org/help/uniprotkb, accessed 15/10/2016): TcoCATL from T. 
congolense, Q26895, TbrCATL from T. b. rhodesiense, Q95PM0, TviCATL from T. vivax, F9WRA9, 
and TcrCATL from T. cruzi, P25779. The amino acid residues involved in the signal peptide are 
highlighted in yellow, those in propeptide in pink, the catalytic domain in blue, the catalytic site I grey, 
the C-terminal extension in green, and the 18-mer TcoCATL N-terminal peptide in red and yellow. 
Alignment characters are annotated as follows: conserved residues (*), strongly similar properties (:) 
and weakly similar properties (.). 
TcoCATL -----MTRTL--RFSVGLLAVAACFVPVALGVLHAEQSLQQQFAAFKQKYSRSYKDATEE 53 
TviCATL -------MHA--HALVTLLAAAVSVAPAAMAVLRADGPVEPLFAAFKQKYGRSYGTAAEE 51 
TbrCATL MPRTEMVRFV--RLPVVLLAMAACLASVALGSLHVEESLEMRFAAFKKKYGKVYKDAKEE 58 
TcrCATL -----MSGWARALLLAAVLVVMACLVPAATASLHAEETLTSQFAEFKQKHGRVYESAAEE 55 
                       . :*.  .... .* . *:.:  :   ** **:*:.: *  * ** 
TcoCATL AFRFRVFKQNMERAKEEAAANPYATFGVTRFSDMSPEEFRATYHNGAEYYAAALKRPRKV 113 
TviCATL AFRLRVFEDNMRRSRMYAAANPHATFGVTPFSDLTPEEFRTRYHNGERHFEAARGRVRTL 111 
TbrCATL AFRFRAFEENMEQAKIQAAANPYATFGVTPFSDMTREEFRARYRNGASYFAAAQKRLRKT 118 
TcrCATL AFRLSVFRENLFLARLHAAANPHATFGVTPFSDLTREEFRSRYHNGAAHFAAAQERARVP 115 
        ***: .*.:*:  ::  *****:****** ***:: ****: *:**  :: **  * * 
TcoCATL VNVSTGKAPPAVDWRKKGAVTPVKDQGACGSCWAFSAIGNIEGQWKVAGHELTSLSEQML 179 
TviCATL VQVPPGKAPAAVDWRRKGAVTPVKDQGTCGSCWSFSAIGNIEGQWAAAGNPLTSLSEQML 177 
TbrCATL VNVTTGRAPAAVDWREKGAVTPVKDQGQCGSCWAFSTIGNIEGQWQVAGNPLVSLSEQML 184 
TcrCATL VKVEVVGAPAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQML 181 
        *:*    ** ***** :**** ***** *****:**:***:* **  **. *..****** 
TcoCATL VSCDTTDYGCRGGLMDKSLQWIVSSNKGNVFTAQSYPYASGGGKMPPCNKSGKVVGAKIS 233 
TviCATL VSCDTKDNGCGGGLMDNAFEWIVKENSGKVYTEKSYPYVSGGGEEPPCKPRGHKVGATIT 231 
TbrCATL VSCDTIDFGCGGGLMDNAFNWIVNSNGGNVFTEASYPYVSGNGEQPQCQMNGHEIGAAIT 238 
TcrCATL VSCDKTDSGCSGGLMNNAFEWIVQENNGAVYTEDSYPYASGEGISPPCTTSGHTVGATIT 235 
        ****. * ** ****:::::***..* * *:*  ****.** *  * *   *: :** *: 
TcoCATL GHINLPKDENAIAEWLAKNGPVAIAVDATSFLGYKGGVLTSCISKGLDHDVLLVGYDDTS 293 
TviCATL GHVDIPHDEDAIAKYLADNGPVAVAVDATTFMSYSGGVVTSCTSEALNHGVLLVGYNDSS 291 
TbrCATL DHVDLPQDEDAIAAYLAENGPLAIAVDATSFMDYNGGILTSCTSEQLDHGVLLVGYNDSS 298 
TcrCATL GHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQLDHGVLLVGYNDSA 295 
         *:::*:**  ** :** ***:*:****:::: *.**::*** *: *:* ******:*:: 
TcoCATL KPPYWIIKNSWSKGWGEEGYIRIEKGTNQCLMKNYARSAVVSGPP---PPPP-------- 339 
TviCATL KPPYWIIKNSWSSSWGEKGYIRIEKGTNQCLVAQLASSAVVGGPGPTPTPTP-------- 337 
TbrCATL NPPYWIIKNSWSNMWGEDGYIRIEKGTNQCLMNQAVSSAVVGGPTPPPPPPP-------- 347 
TcrCATL AVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVGGPGPTPEPTTTTTTSAPG 344 
          *********:. ***.***** **:****: : . ****.**     * 
TcoCATL PPASTFTQEFCEGAECQSGCTKATFPTGKCVQFGGAGSVIASCGSNNLTQIVYPLSSSCS 402 
TviCATL TTNNNNNND-------------RTWPIVKLHEDA-------------LQR---------- 368 
TbrCATL PPSATFTQDFCEGKGCTKGCSHATFPTGECVQTTGVGSVIATCGASNLTQIIYPLSRSCS 410 
TcrCATL PSPSYFVQMSCTDAACIVGCENVTLPTGQCLLTTSGVSAIVTCGAETLTEEVFLTSTHCS 415 
               :               * *  :                  * . 
TcoCATL GFSIPLTVPLDKCLPIVVGSVMYECSGKAPTESARLVRHE------------ 442 
TviCATL ---------------------------------------------------- 
TbrCATL GLSVPITVPLDKCIPILIGSVEYHCSTNPPTKAARLVPHQ------------ 450 
TcrCATL GPSVRSSVPLNKCNRLLRGSVEFFCGSSSSGRLADVDRQRRHQPYHSRHRRL 467 
24 
 
1.3.2 Metallopeptidases 
Metallopeptidases are hydrolases that  perform nucleophilic attack of peptide bonds with the 
help of a water molecule (Barrett et al., 2012). These enzymes need a divalent metal cation, 
such as manganese, copper or zinc, to activate the water molecule. The metal ion is positioned 
by three amino acid ligands, namely, Glu320,His297 and His301 (Barrett et al., 2012). 
1.3.2.1 Family M1 reaction mechanism 
 The best characterised family M1 metallopeptidase is E. coli aminopeptidase N (McCaman 
and Villarejo, 1982; Ito et al., 2006). The reaction mechanism for the exopeptidase activity of 
this peptidase was proposed by Ito et al. (2006), as shown in Figure 1.12. 
  
Figure 1.12: Proposed reaction mechanism for E. coli aminopeptidase N. It can be inferred that all 
Family M1 aminopeptidases have a similar mechanism for catalysis (Ito et al., 2006). (a) Free enzyme; 
(b) Michaelis complex; (c) tetrahedral intermediate; (d) enzyme complexed with the amino acid product. 
The residues necessary for catalysis are the Glu320 of the “HEXXH” motif and an additional 
Tyr381, while the function of the two histidine residues, His297 and His301, is to bind the divalent 
cation (Zn2+). As depicted in Figure 1.12 (a), the first step of catalysis is the hydrogen bonding 
of Glu298 to a water molecule. The effect of this bond and the proximity of the zinc ion makes 
the water molecule strongly nucleophilic. The substrate is brought into the active site forming 
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a Michaelis complex (Figure 1.12, b) by the interaction of the carbonyl oxygen of the substrate 
with the hydroxyl group of Tyr381 and Zn2+. At this point, the amine group of the substrate 
interacts with the hydroxyl group Glu298, allowing the formation of the enzyme-substrate 
complex. 
Hydrolysis is initiated by the nucleophilic attack of the water molecule on the carbonyl carbon 
of the substrate (Figure 1.12, c). The hydroxyl group of Tyr381 is thought to stabilise this 
reaction intermediate. Following the nucleophilic attack by the water molecule, the amine 
group linked to the rest of the peptide substrate is released, leaving the N-terminal amino acid 
residue linked to the enzyme via the Zn2+ (Figure 1.12, d). This amino acid product is released 
when it is replaced by a second water molecule (Ito et al., 2006; Mucha et al., 2010). 
1.3.2.2 Aminopeptidases 
Aminopeptidases constitute a diverse set of exopeptidases with essential roles in a wide range 
of cellular functions. These enzymes catalyse the removal of amino acids from the N-terminus 
of polypeptides; the specific residues for which they show an affinity, as well as their structure, 
determine their subdivision into families (Drinkwater et al., 2017).  
Aminopeptidases belong to the clan MA which includes metallopeptidases that bind divalent 
cations (Figure 1.12). Within clan MA, aminopeptidase is found in families M1 and M17 
(Rawlings et al., 2009). Aminopeptidases all possess the conserved exopeptidase motif 
“GXMEN” which distinguishes them from the closely related leukotriene A4 hydrolases, which 
are also found in family M1 (Barrett and Rawlings, 2007). The most pertinent difference 
between the two families is the conserved metallopeptidase motif “HEXXH”, absent in family 
M17 aminopeptidases, but present in family M1 aminopeptidases (Mucha et al., 2010). The 
Glu of the motif and a Tyr residue are thought to be necessary for catalysis (Hooper, 1994). 
Also, aminopeptidases belonging to family M1 (Figure 1.13), bind a single divalent cation, 
while M17 aminopeptidases bind two. M17 aminopeptidases are only active as homo-
hexamers whereas family M1 aminopeptidases are active as monomers (Matsui et al., 2006). 
Sub-classification of aminopeptidases is based primarily on the number of amino acids 
cleaved from the N-terminus of substrates. Aminopeptidases cleave a single amino acid from 
the N-terminus while diaminopeptidases or aminodipeptidases remove a dipeptide from the 
N-terminus (Barrett et al., 2012). 
The classification of aminopeptidases is also dependent on the relative efficiency by which the 
enzyme removes different amino acids from the N-terminus. To date, leucine 
aminopeptidases, belonging primarily to family M17, have been prominently discussed, but 
argininyl-, methionyl-, aspartyl-, alanyl- (mostly family M1), glutamyl-, prolyl-, and cysteinyl-
aminopeptidases have also been described (Rawlings et al., 2009). However, nomenclature 
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such as “leucine aminopeptidase” may be misleading since the specificity of the enzyme in 
vitro is usually determined using single amino acid synthetic substrates (e.g. H-Leu-AMC) 
which differ from more physiologically relevant substrates, such as peptide hormones 
including angiotensins (Taylor, 1993; Matsui et al., 2006; Rawlings et al., 2009). Also, although 
the metal ion used in activity assays appears to affect substrate preferences, different 
protocols use a variety of divalent cations, all of which have different effects on the catalytic 
activity of aminopeptidases (Taylor, 1993).  
Aminopeptidases may also be classified based on the location of the enzyme within the cell. 
Some aminopeptidases are secreted, but most tend to either be membrane-bound (usually 
family M1) or cytosolic enzymes (usually family M17). Also, aminopeptidases may be localised 
to a single type of organelle, such as lysosomes, nuclei or mitochondria (Barrett et al., 2012). 
Membrane-bound aminopeptidases and methionine specific aminopeptidases are both 
redundantly referred to as aminopeptidase M. Therefore; it is possible for structurally unrelated 
enzymes to have the same name and be located in different locales of the cell (Barrett et al., 
2012). Further distinctions between aminopeptidases may be made on the basis of their 
relative inhibition by bestatin or puromycin; metal ion co-factor and pH of optimal activity 
(Taylor, 1993). Aminopeptidases are inhibited by bestatin, amastatin and metal-chelating 
agents such as EDTA and 1,10 phenanthroline (Mucha et al., 2010). Puromycin specifically 
inhibits M1 aminopeptidases and has been used to tell between cytosolic aminopeptidases 
and membrane-bound aminopeptidases which both belong to the family M1 (Gros et al., 
1985). 
The large family of M1 aminopeptidases (clan MA, family M1) are zinc-dependent enzymes 
characterised by the presence of two conserved, catalytic sequence motifs; a consensus zinc-
binding motif (HEXXH-(X18)-E) and the ‘GXMEN’ exopeptidase motif (Barrett et al., 2012). 
Excluding viruses, M1 aminopeptidases are distributed throughout all phyla and have been 
implicated in a wide range of functions including cell maintenance, growth and development 
and defence. Their wide range of essential functions in combination with their presence in 
such a wide distribution of organisms shows the importance of the family and has led many 
research groups to assess their utility as therapeutic targets for both infectious and chronic 
diseases of humans and other animals.  
Many parasite aminopeptidases have been investigated, including the aminopeptidases of the 
protozoan parasites Plasmodium falciparum (Mistry et al., 2014), P. vivax (Kang et al., 2015), 
T. b. brucei (Timm et al., 2017), T. cruzi (Cadavid-Restrepo et al., 2011), the parasitic flukes 
Schistosoma mansoni (Maggioli et al., 2017), and Fasciola hepatica (Maggioli et al., 2011); 
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the nematodes Heterodera glycines (Masler, 2004). A summary of the recently investigated 
parasite aminopeptidases is shown in Table 3.1. 
 
 
 
 
 
 
 
Figure 1.13: Structure and conservation of M1 aminopeptidases. (A) X-ray crystal structure of 
human aminopeptidase N coloured based on domains with domain I in teal, domain II in orange, domain 
III in magenta, and domain IV in blue. (B) Crystallographically determined dimer of aminopeptidase N 
(APN) which is said to occur on the cell surface via its attachment to the domain I (teal). (C-E) 
Characteristic structures of M1 aminopeptidases coloured according to sequence conservation (high 
conservation is purple, the average is white and low is cyan). Sequence alignments and conservation 
calculations performed using ConSurf http://consurf.tau.ac.il/2016/credits.php): (C) the M1 
aminopeptidase from P. falciparum (PfA-M1), (D) human endoplasmic reticulum aminopeptidase 1 
(ERAP1), (D) human leukotriene A4 hydrolase (LTA4H).(Drinkwater et al., 2017). 
The main role proposed for these aminopeptidases in P. falciparum and S. mansoni is the 
proteolysis of ingested haemoglobin into single amino acids, which are subsequently used for 
necessary metabolic processes of the parasite (Stack et al., 2007; Song et al., 2008). Given 
that these enzymes seem to play an essential role in parasite development, aminopeptidase 
inhibitors seem to be effective in decreasing the growth of various intracellular parasites in 
vitro, most notably Leishmania spp., and P. falciparum as well as the extracellular T. b. brucei 
(Knowles, 1993; Flipo et al., 2007). The most promising of these studies resulted in the 
identification of a compound based on a malonic hydroxamic template, which has proven to 
be a selective inhibitor of PfA-M1, the family M1 aminopeptidase of P. falciparum. The inhibitor 
has been shown to reduce the growth of parasites in vitro and has good physiochemical and 
pharmo-kinetic properties (Flipo et al., 2007; Skinner-Adams et al., 2010). 
There have been several attempts to use aminopeptidases as vaccines against parasitic 
diseases, most notably for fascioliasis and haemonchosis (Piacenza et al., 1999; Reszka et 
al., 2007; Acosta et al., 2008). Interestingly, the fascioliasis vaccination included two cathepsin 
L-like cysteine peptidases together with the leucyl aminopeptidase of F. hepatica. The group 
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of animals receiving the mix of all three enzymes was significantly protected (78%) while the 
best level of protection (89%) was achieved by vaccination with the leucyl aminopeptidase 
alone (Piacenza et al., 1999). In addition, the leucyl aminopeptidase of F. hepatica has been 
shown to be an immunodominant antigen and could potentially be used for the serological 
diagnosis of fascioliasis in humans (Marcilla et al., 2008). 
 Table 1.3: Summary of several characterised parasite aminopeptidases. 
Species Family Substrate 
specificities 
References 
Babesia bovis MAP H-Met-AMC (Munkhjargal et al., 
2016) 
Clonorchis sinensis M17 H-Leu-AMC (Kang et al., 2012) 
Cryptosporidium 
parvum 
M17 H-Leu-AMC (Kang et al., 2011) 
Eimeria tenella M1 H-Ala-AMC 
H-Arg-AMC 
(Gras et al., 2014) 
Plasmodium 
falciparum 
M1 H-Ala-AMC 
H-Met-AMC 
(Poreba et al., 2012) 
Trypanosoma cruzi M17 H-Leu-AMC (Cadavid-Restrepo 
et al., 2011) 
1.4 Recombinant Protein Expression 
In recent years, much research and resources have been put into the development and 
improvement of large-scale recombinant protein production in biotechnology. Diagnostic 
agents, vaccines, growth factors and hormones depend on recombinant technology for their 
large-scale production (Mogk et al., 2002). Much effort is invested in developing methods to 
produce the maximum yield of a properly folded and active protein. However, the recombinant 
overproduction of proteins in various heterologous expression systems often results in 
recombinant protein misfolding and aggregation (Kiefhaber et al., 1991; Stegemann et al., 
2005). Prokaryotic systems, such as E. coli, are the principal hosts for recombinant expression 
since they are well understood compared to yeast and mammalian cell systems and therefore 
more easily genetically engineered and have the potential to produce large quantities of 
recombinant protein inexpensively (Mogk et al., 2002).  
1.4.1 E. coli host expression system 
The advantages of the E. coli expression system include: easy cell growth, using relatively 
simple and widely available laboratory equipment; the genotypes and phenotypes of E. coli 
are well-known; it is the cheapest option; recombinant gene expression can be achieved from 
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cloning to pure protein product in as little as two weeks and the resources for optimising 
expression such as vectors and host strains are easily accessible (Fakruddin et al., 2012). 
The main disadvantage of using E. coli as an expression host is the lack of protein biosynthesis 
machinery for the expression of eukaryotic proteins since E. coli is a prokaryote. 
Consequently, post-translational modifications such as glycosylation and eukaryote-specific 
codon sequences which are critical for proper folding of eukaryote-sourced proteins are 
missing in E. coli (Brown, 1995). 
1.4.1.1 Protein folding inside the E. coli cell 
Initially protein folding was thought to go through specific folding pathways to be transformed 
into the native structure speedily. However, proteins have been observed to achieve the 
correct conformation form various unfolded states. The mechanism of protein folding without 
a catalyst is presented in Figure 1.14. The native protein form represents the desired least-
energy state form of the protein at the bottom of the funnel. Every other non-native form of a 
protein is at a higher energy state. Protein folding can therefore be imagined as protein striving 
to reach the lowest energy state as it “rolls” down the folding funnel. The folding funnel 
represents the various protein folding pathways a protein can go through from an unfolded 
state to the native minimum energy state which can progress fast or slow depending on the 
pathway followed (Schultz, 2000). Protein folding is an error-prone process, especially for 
large proteins. Over time incompletely folded protein intermediates with their exposed 
hydrophobic amino acid side chains may accumulate and thereby promote aggregation. The 
higher the concentration of these protein intermediates the higher the likelihood of protein 
aggregation occurring. Protein intermediates with incorrect disulfide bonds or prolyl peptide 
bonds are also prone to aggregation. This is circumvented by the expression of disulfide 
isomerase and peptidyl prolyl isomerase, responsible for the respective bond formation in the 
correct conformation, by the cell where folding is occurring (Schiene and Fischer, 2000).  
Protein folding within cells is much more complex than in in vitro folding experiments. The 
biosynthesis of proteins occurs at the ribosomes from the N to the C-terminus in a vectoral 
manner. In in vitro experiments, protein folding is performed within diluted protein solutions 
and complete polypeptide chains, whereas in vivo the nascent polypeptides produced by the 
ribosome do not contain all the information necessary for folding (Mogk et al., 2002).  The 
highly dense environment of the cytosol increases the probability of nascent polypeptides and 
protein intermediates inappropriately interacting by hydrophobic interaction leading to 
misfolding and aggregation. Therefore, nascent polypeptides are required to fold as soon as 
possible, while proteins destined for other localisations should be translocated in an unfolded 
state. Due to ceaseless thermal atomic vibrations, native conformed proteins could 
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spontaneously unfold and lose activity, this is due to the conformational flexibility that native 
proteins have that is essential for protein function (Mogk et al., 2002). Environmental stress 
conditions, for example a sudden temperature increase, can cause protein unfolding, 
degradation or aggregation of proteins. Therefore, to optimise cellular protein folding, 
protective systems have evolved over time consisting of families of highly conserved proteins 
named molecular chaperones (Mogk et al., 2002). 
 
Figure 1.14: Protein folding energy funnel. In this representation, the “funnel” contains many local 
energy minima, in which a protein can settle during the folding process. Some minima are folding 
intermediates with native like structures whereas others are more misfolded intermediates (Schultz, 
2000). 
1.4.1.2 E. coli molecular chaperone co-overexpression 
Recombinant protein misfolding can be attributed to the limited availability of molecular 
chaperones of the E. coli host. The use of molecular chaperones is one of the standard 
approaches to improving the soluble recombinant expression of proteins in E. coli (Shuo-shuo 
et al., 2011). Molecular chaperones are vital in the correct folding of newly synthesised 
proteins to their active state and also maintain the three dimensional structure of proteins by 
refolding misfolded and aggregated proteins, as shown in Figure 1.15 (de Marco et al., 2007). 
The Hsp70 system (DnaK with co-chaperones DnaJ and GrpE), Hsp60 system (GroEL with 
GroES co-chaperone) and the ribosome-associated trigger factor are proposed to be the most 
vital chaperones for protein folding in E. coli (Hartl and Hayer-Hartl, 2002). Before molecular 
chaperone studies were common, it was thought that protein aggregation was an 
unsurmountable problem in recombinant expression systems. However, it has been 
demonstrated several times that protein aggregates can be disaggregated and refolded to 
their native state (Mogk et al., 1999).  
In one comprehensive study of molecular chaperone co-expression, the co-overproduction of 
the main cytosolic molecular chaperones in E. coli cells combined with disrupting ongoing de 
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novo protein synthesis in a two-step procedure resulted in improved solubility of 45 out of the 
64 recombinant proteins that were assayed (de Marco et al., 2007). 
 
Figure 1.15: Recombinant expression of recombinant protein (A) with and (B) without 
recombinant molecular chaperone co-expression. (A) With insufficient amounts of molecular 
chaperones the probability of inclusion body formation is high whereas (B) recombinant co-
overexpression of molecular chaperones together with recombinant protein increases levels of correctly 
folded recombinant protein (Mogk et al., 2002). 
A myriad of recombinant proteins has been co-expressed with recombinantly over-expressed 
molecular chaperones in the hopes of improving solubility and correct folding of the desired 
recombinant protein (Table 1.4).
32 
 
Table 1.4: Summary of several recombinant molecular chaperone co-expression studies. Adapted from Betiku (2006)/ 
Molecular chaperone Protein substrate Effect on solubility References 
DnaK-DnaJ-GrpE Human growth factor Co-expression inhibits inclusion 
body formation and improves 
recombinant protein solubility 
from 5% to >85% of total 
recombinant protein 
(Blum et al., 1992) 
GroEL-GroES Protein-tyrosine kinase P50csk More than 50% of the total 
recombinant protein is soluble 
following co-expression 
(Amrein et al., 1995) 
Trigger factor Porcine epidemic diarrhoea virus 
spike glycoprotein 
Soluble recombinant fragment of 
up to 7.5 mg/l was produced upon 
co-expression 
(Piao et al., 2016) 
GroEL-GroES and trigger factor Oxygen-regulated protein (ORP) 
150 
Approximately 86% of total 
recombinant ORP150 is soluble  
(Nishihara et al., 1998) 
CD137 ligand A yield of 3 mg/L of pure soluble 
recombinant protein was obtained 
after co-expression 
(Wang et al., 2012) 
GroEL-GroES and DnaK-DnaJ-
GrpE 
Lipase-948 Co-expression resulted in soluble 
recombinant protein of 19.8% of 
total 
(Shuo-shuo et al., 2011) 
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1.4.2 Statistical approaches to soluble recombinant protein expression 
The standard approach to protein expression optimisation is usually performed by measuring 
one factor at a time to the experiments response while the other factors are kept constant. 
This approach is known as one factor at a time (OFAT). This approach has a major 
shortcoming in that it does not allow for the analysis of the interacting effects of the factors 
being measured. Consequently, factor interactions are undetected which makes this approach 
time-consuming (Noguère et al., 2012).  
A more systematic approach to testing factors has gained popularity in recombinant protein 
production namely the factorial approach. This approach is defined by the combinations of all 
states of the experimental factors. The bouquet of techniques that comprise the factorial 
approach is known as statistical design of experiment and has the advantage of allowing the 
identification of the crucial factors of any process such as recombinant protein expression 
(Papaneophytou and Kontopidis, 2014). 
Protein expression experiments are often started with limited information on which factors are 
important for each individual protein. Subsequently, it is advisable to test as many factors as 
possible. This can be done efficiently by using a two-level full factorial design resulting in a 
design matrix. The important trait of this design is that the results of each experiment generate 
information about the interaction and effects of all the factors examined (Papaneophytou and 
Kontopidis, 2014). 
1.5 Aims and objectives of current study 
1.5.1 General objective 
Three trypanosomal antigens have been identified as potential diagnostic markers for AAT 
namely, the full-length inactive mutant T. vivax cysteine peptidase FLTviCATLC25A and the two 
T. congolense family M1 aminopeptidases, TcoAP1 and TcoAP2. The overall objective of this 
study was to optimise standardised protocols for the soluble reombinant production of these 
antigens in an E. coli expression system for their eventual use in the development of point of 
care serodiagnostic assays that are affordable to end-users.  
1.5.2 Aims 
1. To investigate the effect of several factors on the soluble recombinant expression of 
FLTviCATLC25A in the E. coli expression system using a statistical approach. 
2. To produce antibodies against the FLTviCATLC25A antigen for examination of antigen 
detection within parasite lysates as a measure of diagnostic potential. 
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3. To investigate the effect of recombinant co-expression of several molecular chaperone 
teams with TcoAP1 and TcoAP2 on soluble recombinant expression of the T. 
congolense antigens i.e. for functional characterisation.  
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Chapter 2: RECOMBINANT EXPRESSION OPTIMISATION OF 
THE TRYPANOSOMA VIVAX ANTIGEN FLTVICATLC25A 
2.1 Introduction 
Trypanosoma vivax is a principal causative agent of trypanosomosis in African livestock 
(Lalmanach et al., 2002). Control and therapeutic methods for this disease are required due 
to the negative impact it has on the economy of sub-Saharan Africa (Antoine-Moussiaux et 
al., 2009). The diagnosis of trypanosomosis is a process that can provide sufficient and 
accurate information on the disease to allow for appropriate therapeutic measures to be taken 
(Giordani et al., 2016). A range of diagnostic tests that are used include serological, 
parasitological, molecular and clinical tests. Diagnostic techniques used should be appropriate 
for use in the field and for the level of technology available in developing countries (Büscher, 
2014). 
Clinical diagnosis is dependent on the physical examination of cattle. The major problem with 
this technique is that the clinical signs are not specific for trypanosomosis (Büscher, 2014). 
Parasitological techniques involve viewing of wet blood films and Giemsa-stained thick and 
thin fixed blood films under a light microscope. This technique varies in sensitivity due to 
similarities in the morphology of trypanosome species (Holmes, 2013). For this reason, a 
haematocrit centrifuge can be used to increase the sensitivity by separating the buffy coat, 
containing the trypanosomes, from the blood cells and plasma. The disadvantage of using this 
technique, especially in the field, is that fresh blood, a haematocrit centrifuge and a 
microscope are needed (Büscher, 2014). Various PCR assays exist for the diagnosis of AAT 
and species identification, but none has been validated for diagnostic purposes. In theory, a 
PCR assay which targets repetitive sequences is more sensitive than those that target single 
copy or low copy sequences such as those developed for the distinction between T. b. 
gambiense and T. b. rhodiense. High specificities have been reported by most PCR studies. 
However, comparisons of their diagnostic abilities to those of commonly used diagnostic tests 
were not made (Tiberti et al., 2013). An effective PCR diagnostic assay which used TviCATL 
gene sequences as genetic markers were found to be species-specific when evaluated 
against other trypanosome species. The problem with performing this technique in the field is 
that it is costly since it involves the use of specialised equipment by an experienced technician. 
The most promising techniques for field use, especially for diagnosing T. vivax infections, are 
serological techniques, such as the enzyme-linked immunosorbent assay (ELISA) (Osório et 
al., 2008). The advantage of the ELISA technique is that it can be adapted for field use, into 
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simple to use lateral flow devices which are RDTs. This technique also allows for the 
processing of a large number of samples due to this adaptation (Büscher, 2014). 
There are two types of ELISAs that can be used for diagnosis namely, the antibody-detection 
ELISA (Boulangé et al., 2017) and the antigen-detection ELISA (Nantulya and Lindqvist, 
1989). The low availability of standardised recombinant trypanosome antigens for the 
detection and production of anti-trypanosome antibodies is a significant problem for both the 
antibody-detection ELISA and the antigen-detection ELISA.  Up until now, ELISAs for both 
antibody and antigen detection has relied on the crude preparation of whole parasite lysate 
and native antigens acquired from infected rats; therefore, it is difficult to optimise and 
standardise the tests, and a large volume of cultured trypanosomes is required (Magez and 
Radwanska, 2014). Due to this problem, research has increased on the identification and 
recombinant expression of antigens that show promise for the detection of T. brucei (Tran et 
al., 2008), T. congolense (Pillay et al., 2010) and T. evansi (Tran et al., 2009) infections in the 
sera of infected animal species. 
There is currently no suitable antigen for the specific diagnosis of T. vivax infections (Boulangé 
et al., 2017). For this reason, this study focussed on optimising the production of a 
recombinant antigen that could potentially be used to detect T. vivax infections. The antigen 
of concern was based on the T. vivax cathepsin L-like peptidase, TviCATL. The single putative 
full length cathepsin L-like gene (UniProtKB ID: F9WRA9) identified in T. vivax strain Y486 
(TviCATL) codes for a protein of 454 amino acids in length with an expected molecular weight 
of 48 kDa and a theoretical pI of 7.51 as predicted by the Compute pI/MW tool on the ExPASy® 
server (Gasteiger et al., 2005). FLTviCATLC25A is the C25A mutation of TviCATL and is also 
fused to the Trx TagTM (19 kDa) giving the recombinant protein a total molecular weight of 67 
kDa. Previously the inactive full-length form of TcoCATL showed relatively improved 
expression when compared to the active form of the peptidase (Authié, 1994; Pillay et al., 
2010; Boulangé et al., 2011). Furthermore, in previous studies, only the catalytic domain of 
TcoCATL was expressed because this too showed better recombinant expression when 
compared to the full-length active construct of the peptidase (Pillay et al., 2010). 
The specificity of antibody detection assays is completely dependent on the homogeneity of 
the diagnostic antigen. Common antigen preparation protocols used in complement fixation 
tests (CFT), western blot or ELISA are made up of crude lysates cultured in vitro or in vivo 
from the trypanosome that is subject to investigation. Consequently, it is usual for cross-
reactivity to occur from other African trypanosome infections and even with non-trypanosome 
parasites (Büscher, 2014). Due to high cross-reactivity observed between the trypanosome 
species in ELISA, it is vital to test infected sera using species-specific antigens (Büscher, 
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2014).  Therefore, the production of FLTviCATLC25A, which has the potential to be specific for 
T. vivax infection detection and stable enough to fulfil the ASSURED criteria of lateral flow 
tests (Vather, 2010), could potentially be used in conjunction with the existing recombinant 
antigens, such as the full-length inactive mutant of TcoCATL, to increase the sensitivity and 
robustness of the immunoassays.  
2.2 Materials and methods 
2.2.1 Materials 
Molecular Biology: EcoRI, NotI [for nomenclature see (Roberts et al., 2003)], Shrimp alkaline 
phosphatase (SAP), T4 DNA ligase, O’GeneRulerTM 1 kb DNA Ladder, 10 mM dNTPs, high 
fidelity PCR enzyme mix, GeneJetTM Plasmid Miniprep Kit, 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (IPTG) and the pTZ57R/T vector were obtained from Thermo Scientific 
(Waltham, MA, USA). The pET32-a expression vector was purchased from Novagen 
(Darmstadt, Germany) and the pGEX4T-1 expression vector from GE Healthcare (Uppsala, 
Sweden). FIREpol® Taq polymerase, 10 x PCR reaction buffer and 25 mM MgCl2 were from 
Solis Biodyne (Tartu, Estonia). Bacteriological agar, tryptone and yeast extract were 
purchased from Merck Biolab (Darmstadt, Germany). Crystal violet and ethidium bromide 
were purchased from Sigma (St. Louis, MO, USA). The ZymoResearch Clean and 
ConcentratorTM kit was obtained from Zymo Research (Orange, CA, USA) and the E.Z.N.A® 
gel extraction kit from PEQlab (Erlangen, Germany). Seakem® LE agarose was purchased 
from Lonza (Rockland, ME, USA) and ampicillin sodium salt from Amresco (Solon, OH, USA). 
E. coli cells: Competent E. coli cells, JM 109 and BL21 (DE3) strains, were purchased from 
New England Biolabs (Ipswich, MA, USA). The JM109 E. coli permits blue/white screening for 
transformants in the presence of IPTG and X-gal. The BL21 (DE3) E. coli are deficient in both 
Lon and OmpT protease expression (Miroux and Walker, 1996). 
Purification and quantification of recombinant proteins: His-select® nickel affinity resin, 
dialysis tubing (10 kDa size cut-off), polyethylene glycol (PEG) Mr 20 000, 4-chloro-1-naphthol, 
phosphorylase B (97.4 kDa), bovine serum albumin (BSA, 68 kDa) ovalbumin (45 kDa), 
carbonic anhydrase (30 kDa), soybean trypsin inhibitor (SBTI, 21.5 kDa), myoglobin (14 kDa), 
lysozyme (14 kDa) and the semi dry blotter were obtained from Sigma (St. Louis, MO, USA). 
The PageRulerTM prestained protein ladder was purchased from Pierce (Rockford, IL, USA) 
the Amicon® centrifugal concentrators from Merck Millipore (Billerica, MA, USA) and the 
BioTraceTM nitrocellulose from PALL Corp (Anne Arbor, USA). 
Immunochemical techniques: Freund’s complete and incomplete adjuvants, rabbit anti-
chicken IgG HRPO conjugate and bovine serum albumin (BSA) were purchased from Sigma 
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(St. Louis, MO, USA), polyethylene glycol (PEG) Mr 6 000 was purchased from Merck 
(Darmstadt, Germany) and Nunc-ImmunoTM Maxisorp 96-well plates from Nunc Intermed 
(Roskide, Denmark). The 2, 2’-azinobis [3-ethyl-3, dihydrobenzithiazole-6-sulfonate] (ABTS) 
ELISA chromogen was purchased from Roche (Mannheim, Germany) and the BIOTEK® 
ELx50TM Microplate washer from Biotek Instruments Inc. (USA). 
2.2.2 Calibration curves for DNA fragment and protein size determination 
Standard curves were drawn for molecular weight markers separated on a 1% (w/v) agarose 
gel (Figure 2.1, A) and on a 12.5% reducing SDS-PAGE gel (Section 2.2.7). The relative 
mobility of each DNA fragment or protein marker was plotted against the log of the number of 
base pairs (bp; Figure 2.1, A) or the respective relative molecular mass (Mr; Figure 2.1, B). 
Figure 2.1: Standard curves relating relative mobility to the log of the base pairs and molecular 
weight markers used in agarose and 12.5% reducing SDS-PAGE gels. (A) O’GeneRulerTM 1 kb 
DNA ladder was used for agarose electrophoresis. The equation of the trend line is given by y = -
0.3406x + 1.5982, with a correlation coefficient of 0.991. (B) The molecular weight marker used for 
reducing SDS-PAGE consisted of standard proteins of known size as indicated. The equation of the 
trend line is given by y = -0.9216x + 2.1001, with a correlation coefficient of 0.98. 
2.2.3 Protein quantitation 
2.2.3.1 Bradford protein assay 
The Bradford (1976) assay was performed to determine the protein concentration. To obtain 
a standard curve (Figure 2.2), a 1 mg/ml BSA stock was used to prepare dilutions (20 µg/ml - 
100 µg/ml) in triplicate. Protein standards (100 µl) were mixed with 900 µl of Bradford reagent 
[0.12 % (w/v) Coomassie brilliant blue G-250 dissolved in a 2 % (v/v) perchloric acid solution]. 
The absorbance at 595 nm was recorded after 15 min of incubation. 
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Figure 2.2 Standard curve for the Bradford protein assay. Bovine serum albumin standards ranging 
from 20 to 100 µg/ml were added to the Bradford reagent and the resulting absorbance values 
measured at 595 nm after incubation at 37oC for 30 min. The equation of the trend line is y = 0.0143x 
+ 0.0959 with a R2 value of 0.982. The absorbance readings at 595 nm represent the average of 
quintuplicate experiments after 15 min development.  
2.2.3.2 Monitoring soluble recombinant protein expression level by western blot 
analysis 
The amount of soluble recombinant FLTviCATLC25A upon expression was estimated by 
western blot. The intensity of protein bands on the nitrocellulose membrane was measured by 
densitometry using the G-Box system (GeneSys®) and GelAnalyzer® 2010a software (Lazar 
and Lazar, 2010). The yield of FLTviCATLC25A was calculated in arbitrary units, comparing the 
amount of FLTviCATLC25A in the soluble fraction of samples to the amount of FLTviCATLC25A 
in the whole cell lysate.  
2.2.3.3 Statistical analysis 
Design-Expert 10 software (Stat-Ease Inc) was used for the full factorial analysis of the 
experimental data. The quality of the fit to the non-linear model equation was expressed by 
the coefficient of correlation R2 and the significance of regression coefficient was tested by 
analysis of variance (ANOVA). 
2.2.4 Sub-cloning of the FLTviCATLC25A gene into the bacterial pET32-a expression 
vector 
FLTviCATLC25A had been previously cloned into the pT57R cloning vector and transformed 
into JM109 E. coli cells in our laboratory. Recombinant FLTviCATLC25A-pT57R plasmids (20 
µl) were subjected to restriction enzyme digestion with NotI in buffer O at RT for 16 h with 
subsequent heat deactivation at 80oC for 20 min. The resultant reaction mixture was incubated 
with EcoRI in its unique buffer at RT and incubated overnight and thereafter inactivated at 
65oC for 15 min. The restriction mixture (50 µl) was added to 1/6 volume of gel loading buffer 
and electrophoresed on a 1% (w/v) agarose gel in TAE buffer, both containing crystal violet 
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(10 µg/ml). Crystal violet was used instead of ethidium bromide to visualise bands before 
excision (Rand, 1996). Using ethidium bromide at this point in the cloning process would 
require visualisation with UV light which damages the DNA and would result in a less efficient 
cloning process. The gel was subsequently viewed on a lightbox, the 1300 bp product was 
excised and subsequently purified using the E.Z.N. A® gel extraction kit according to the 
manufacturer’s instructions. 
The pET32-a (Figure 2.3) and pGEX4T-1 expression vectors were each subjected to 
restriction enzyme digestion (20 µl) with NotI in buffer O at RT for 16 h with subsequent heat 
deactivation at 65oC for 15 min. The resulting reaction mixture was incubated with EcoRI in its 
unique buffer at RT for 16h and thereafter heat inactivated at 65oC for 15 min. Subsequently, 
1 U of SAP was added and incubated at 37oC for 1 h to dephosphorylate the vector. A 3:1 
ratio of vector to gene insert was incubated with 6 U of T4 DNA ligase at 37oC for 1 h followed 
by a further incubation step at RT for 16 h. 
 
Figure 2.3: Map of the pET-32a expression vector showing the multiple cloning sites (Novagen 
technical manual). 
The ligation mixture was transformed into competent E. coli BL21 (DE3) cells by heat shock 
transformation (Cohen et al., 1972; Sambrook and Russell, 2001). Briefly, 10 ml of 2 x YT 
1.6% (w/v) Tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl] liquid medium was inoculated 
with a single E. coli BL21 (DE3) colony and subsequently grown at 37oC for 16 h with agitation. 
Thereafter 1 ml of the overnight culture was diluted 1:100 with 99 ml of fresh 2 x YT liquid 
medium and grown at 37oC with agitation until an OD600 of 0.3 to 0.4 was reached. The cultures 
were transferred into ice-cold, sterile centrifuge tubes and incubated on ice for 10 min. The 
cells were pelleted (4 500 g, 10 min, 4oC) and resuspended in ice-cold, sterile CaCl2 solution 
[60 mM CaCl2, 10 mM HEPES, pH 7.0 (40 ml)]. The cell solution was pelleted again (4 500 g, 
41 
 
10 min, 4oC) and resuspended in ice-cold, sterile CaCl2 solution (2 ml). The competent cells 
(20 µl) were incubated with the ligation mixture (1 µl) on ice for 30 min. Thereafter, cells were 
heat shocked at 42oC for 90 s and incubated on ice immediately for 2 min. The cells were 
added to pre-warmed super optimal cataboliser with catabolite repression (SOC) medium [2% 
(w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose (80 µl)] and incubated at 37oC for 1 h with gentle agitation. The 
resulting cell mixture (100µl) was plated onto two pre-warmed 2 x YT plates (containing 50 
µg/ml ampicillin) and incubated at 37oC for 16 h. 
Recombinant FLTviCATLC25A-pET32a and FLTviCATLC25A-pGEX4T-1 colonies were grown in 
10 ml of 2 x YT liquid medium (containing 50 µg/ml ampicillin) and grown at 37oC for 16 h with 
agitation. The plasmid DNA was isolated using the GeneJetTM Plasmid Miniprep Kit, according 
to manufacturer’s instructions and was subjected to a small scale restriction digestion (5 µl) 
with NotI and EcoRI simultaneously in buffer O at 37oC for 4 h. Restriction digestion products 
(10 µl), resulting from the NotI and EcoRI restriction enzyme digestions, were added to 1/6 
volume of GLB and analysed on a 1% (w/v) agarose gel, containing ethidium bromide (0.5 
µg/ml), in TAE buffer to test for positive clones. The plasmid DNA of the positive clones were 
then used as the positive template for colony PCR. The master mix for the PCR reaction 
contained FLTviCATL Fw and Rv primers (0.25 µM for each; Table 2.1), 1x High Fidelity PCR 
enzyme mix buffer, 2.5 mM MgCl2, 0.25 U FIREPol® Taq polymerase and 0.5 mM dNTPs in a 
total reaction volume of 25 µl. The PCR was carried out by denaturing the plasmid DNA at 
95oC for 5 min, followed by 30 cycles of denaturing the DNA at 95oC for 1 min, primers 
annealed at 60oC, 64.3oC or 67oC for 1 min, elongation at 72oC for 2 min and finally an 
elongation at 72oC for 7 min. The colony PCR products were added to 6x GLB and 
electrophoresed on a 1% (w/v) agarose gel, containing ethidium bromide (0.5 µg/ml), in TAE 
buffer. 
Table 2.1: Primers used for the screening of recombinant colonies. The restriction sites for EcoRI 
and NotI are underlined. 
Primer Sequence Tm (oC) 
Full length (FL) TviCATL Fw 5’-AAA GAA TTC TAC ATG GCG GTG CTG CGC 
GCG GAG-3’ 
67 
Full length (FL) TviCATL Rv 5’-AAA GCG GCC GCC CTA CCC TCG ATG TTG 
TGC ATC GCA GGG CGG CG-3’ 
78 
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2.2.5 Factors and experimental design 
Three factors of the recombinant protein expression process were chosen to be evaluated by 
the experimental design: temperature, induction duration and IPTG (inducer) concentration 
(Table 2.2). 
Table 2.2: Factors and levels assayed for recombinant expression optimisation 
 Lowest level/Category A Highest level/Category B 
Temperature (oC) 30 37 
Induction duration (h) 4 16 
IPTG concentration (mM) 0 1 
 
A full two-level factorial design 23 was chosen to analyse the statistical effects of the factors 
on the soluble expression of FLTviCATLC25A. This design allows for main effects of the factors 
to be determined, but not their interactions. Due to the considerable variability inherent to 
bioprocesses, the factors were considered significant with p-values lower than 10% (p < 0.1) 
using 90% confidence in the statistical analysis (Design-Expert 10 / Stat-Ease Inc.). 
Single colonies of positively identified recombinant FLTviCATLC25A-pET32a were used to 
inoculate 10 ml of 2 x YT liquid medium containing ampicillin (50 µg/ml). After incubation at 
37oC for 16 h with agitation, 1 ml of the 2 x YT culture was diluted 1:100 with 99 ml of fresh 2 
x YT liquid medium (containing 50 µg/ml ampicillin) and grown at 37oC with agitation until an 
OD600 of approximately 0.7 was reached. Expression was induced with IPTG (0.1 M) at a final 
concentration of 1 mM at 37oC for 4 h with agitation. Ampicillin (50 µg/ml) was added at the 
start of induction as well as after 2 h. The cells were then pelleted by centrifugation (5 000 g, 
10 min, 4oC), the pellets were resuspended in 1% (v/v) Triton X-100-PBS (2 ml), lysozyme 
added (1 mg/ml final concentration) and incubated at 37oC for 30 min. The cell suspension 
was frozen at 70oC for 1 h and subsequently thawed at RT. The cell suspension was then 
sonicated four times for 30 s each, and the cellular debris was subsequently pelleted from the 
soluble protein lysate by centrifugation (5 000 g, 10 min 4oC). The protein lysate was then 
filtered through Whatman No. 1 filter paper and stored at -20oC. 
Samples of the supernatant and the pellet were electrophoresed on two 12.5% reducing SDS-
PAGE gels (Laemmli, 1970) (Section 2.2.7) with one stained with Coomassie blue R-250 and 
the other transferred onto nitrocellulose for western blot analysis (Section 2.2.8).  
2.2.6 12.5% reducing SDS-PAGE analysis 
Protein samples were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) adapted from Laemmli (1970). A discontinuous buffer system was used 
comprising a running gel buffer (1.5 M Tris-HCl, pH 8.8) and a stacking gel buffer (500 mM 
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Tris-HCl, pH 6.8). The protein samples were combined with reducing treatment buffer [125 
mM Tris-HCl, 4% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol]. SDS-PAGE 
was conducted at 40 mA per 2 gels in tank buffer (250 mM Tris-HCl buffer, pH 8.3, 192 mM 
glycine, 0.1% SDS) using the BioRad® Mini protein III electrophoresis apparatus (BioRad, CA, 
USA). After electrophoresis, gels were stained for at least 4 h or for 16 h with Coomassie Blue 
staining solution [0.125% Coomassie Blue R-250, 50% (w/v) methanol, 10% (v/v) acetic acid], 
destained in destaining solution I [50% (v/v) methanol, 10% (v/v) acetic acid] followed by 
complete destaining and gel swelling to their original sizes in several changes of distilled 
water. To determine the molecular weight of proteins of unknown size, a set of standard 
proteins of known sizes were separated using reducing SDS-PAGE. The measurement of the 
relative migration distance (Rf) of individual standard proteins, was used to construct a 
calibration curve to determine the molecular weight of proteins of unknown size (Section 
2.2.2). 
A sensitive silver staining method was used to visualise small amounts of protein on SDS-
PAGE gels (Blum et al., 1987). Following reducing SDS-PAGE, the gel was placed in a 
thoroughly cleaned glass container and incubated with fixing solution [50% (v/v) methanol, 
12% (v/v) glacial acetic acid, 0.5% (v/v) formaldehyde] for 1 h or 16 h at RT on an orbital 
shaker. The gel was rinsed in 50% (v/v) ethanol (3 x 20 min), and soaked in pre-treatment 
solution [0.4% (w/v) Na2S2O3.5H2O] until protein bands were visible. The gel was immediately 
placed in the stopping solution [50% (v/v) methanol, 12% (v/v) acetic acid] for 10 min, and 
subsequently washed in 50% methanol. 
2.2.7 Western blot analysis 
Western blot analysis of proteins was conducted according to the protocol described by 
Towbin et al. (1979). Proteins separated by reducing SDS-PAGE (Section 2.2.7) were 
electrophoretically transferred from the gel onto a nitrocellulose membrane that was briefly 
pre-soaked in blotting buffer [45 mM Tris-HCl buffer, pH 8.3, 173 mM glycine and 0.1% (w/v) 
SDS] using a Sigma Semi-phor® semi-dry blotting apparatus at constant voltage (20 V) and at 
maximum current setting for 55 min. Upon completion of protein transfer to nitrocellulose, the 
effectiveness of protein transfer to the membrane was checked by transiently staining it with 
Ponceau S solution [0.1 % (w/v) Ponceau S in 1% (v/v) glacial acetic acid]. The nitrocellulose 
membrane was destained with several changes of distilled water. All the unoccupied sites on 
the membrane were blocked with blocking solution [5% (w/v) fat-free powder milk in (TBS, 20 
mM Tris-HCl buffer, pH 7.4, 200 mM NaCl)] for 1 h, after which the membrane was washed in 
TBS (3 x 5 min) and subsequently probed for 16 h at 4oC with either anti-6xHis IgY primary 
antibody [1:10 000 diluted in 0.5% (w/v) BSA-PBS] or anti-FLTviCATLC25A IgY [100 µg/ml 
diluted in 0.5% (w/v) BSA-PBS]. The membrane was washed in TBS (3 x 5 min) and incubated 
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in rabbit anti-chicken IgG horseradish peroxidase (HRPO) conjugate [1:15 000 diluted in 0.5% 
(w/v) BSA-PBS] at RT for 1h. Following washing in TBS (3 x 5 min), the membrane was placed 
in substrate solution [(0.06% (w/v) 4-chloro-1naphthol, 0.1% (w/v) methanol, 0.0015% (v/v) 
H2O2 in TBS] until bands were visible. 
2.2.8  Solubilisation, renaturation and purification of recombinant FLTviCATLC25A 
Recombinant proteins are usually the predominant protein when expressed in inclusion bodies 
and are protected against degradation by the host cell’s proteolytic enzymes (Burgess, 2009). 
Renaturation of a protein generally involves the solubilisation of the inclusion bodies using 
chaotropic agents such as guanidine hydrochloride and urea or non-chaotropic agents such 
as SDS and N-lauroylsarcosine sodium salt (sarkosyl) (Burgess, 2009). The solubilised 
proteins are then renatured by removing excess denaturant in an optimised renaturation buffer 
by dilution, dialysis or chromatographic methods (Clark, 1998). The use of immobilised metal 
ion affinity chromatography (IMAC), in this case, a nickel chelate column, allows for the 
gradual removal of the denaturant and the subsequent renaturation of the immobilised 
recombinant protein (Petty, 1996). There are a plethora of commercial screens that help to 
identify suitable renaturation buffers. In the process of renaturing, the protein must undergo 
re-oxidation in order to allow for the formation of disufide bonds in the correct conformation 
and is achieved by either the addition of 0.1 to 1 mM DTT in the inclusion body buffer or within 
the renaturation buffers (Burgess, 2009). 
Sarkosyl solubilisation was performed (Schlager et al., 2012) after 4 h of IPTG (1 mM) induced 
expression at 37oC. The cells were pelleted by centrifugation (5 000 g, 10 min, 4oC), and to 
the pellet, lysis buffer [8 mM Na2HPO4, 286 mM NaCl, 1.4 mM KH2PO4, 2.6 mM KCl, 1% (w/v) 
SDS, pH 7.4, 1 mM DTT (5 ml for a 50 ml culture)] was added. The resulting solution was 
sonicated (2 x 2 min) and subsequently incubated on ice for 30 min. The solubilised proteins 
were separated from the insoluble debris by centrifugation (10 000 g, 20 min, 4oC). Samples 
of the supernatant and the pellet were electrophoresed on a 12.5% reducing SDS-PAGE gel 
(Laemmli, 1970) and stained with Coomassie blue R-250. 
An IMAC column was setup by stacking 1 ml of His-select® nickel affinity resin in a 10 ml 
column container. The column was first washed with 2 column volumes of dH2O then washed 
with 5 column volumes of wash buffer [2.6 mM KCl, 1.4 mM KH2PO4, 286 mM NaCl, 8 mM 
Na2HPO4, 0.1% (w/v) sarkosyl, pH 7.4]. Solubilised protein from the E. coli lysate was added 
to the column and mixed using an end-over-end rotator for 3 h at 4oC. Unbound protein 
fractions were collected, then the column was washed with wash buffer until the 280 nm 
absorbance reached a baseline value of 0.02. The bound proteins were eluted in 1 ml fractions 
with 10 ml elution buffer [50 mM imidazole, 2.6 mM KCl, 1.4 mM KH2PO4, 286 mM NaCl, 8 
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mM Na2HPO4, 0.1% (w/v) Sarkosyl, pH 7.4]. The column was then regenerated using 2 
column volumes of dH2O and 3 column volumes of equilibration buffer (10 mM imidazole, 500 
mM NaCl, 50 mM NaH2PO4, pH 6.8) and stored in 30% (v/v) ethanol at 4oC. Samples of the 
unbound and the eluted fractions were electrophoresed on a 12.5% reducing SDS-PAGE gel 
(Laemmli, 1970) and stained with Coomassie blue R-250. 
The fractions containing the target protein were pooled and concentrated against polyethylene 
glycol (PEG) Mr 20 000 until there was a 5-fold decrease in volume. Protein concentration was 
determined by performing a Bradford assay (Bradford, 1976). Purified samples (10 µl) were 
electrophoresed on a 12.5% reducing SDS-PAGE gel (Laemmli, 1970) and visualised using 
silver stain (Blum et al., 1987). 
2.2.9 Antibody preparation and ELISA evaluation 
2.2.9.1 Preparation of immunogen, the immunisation of chickens and IgY isolation 
Chickens were used to raise antibodies against the purified recombinant FLTviCATLC25A 
protein with the use of these chickens approved by the University of KwaZulu-Natal animal 
research ethics committee (approval number 053/15/Animal). Two chickens were immunised 
intramuscularly on either side of the breastbone. The recombinant FLTviCATLC25A protein (50 
µg/ml, 1.5 ml) was added to an equal volume of Freund's complete adjuvant and triturated to 
form a stable water-in-oil emulsion prior to immunisation. Booster injections, using Freund’s 
incomplete adjuvant, were given at weeks 2, 4 and 6. Eggs collected prior to immunisation 
served as the pre-immune control, and those collected throughout the immunisation schedule 
were stored at 4oC. 
Chicken immunoglobulin (IgY) was isolated from the yolks of the eggs collected at each week 
as described by Goldring and Coetzer (2003). Briefly, the yolks were separated from the egg 
whites and rinsed under running tap water. The yolk sac was punctured, the yolks collected, 
and the volume determined. The yolk was mixed with two yolk volumes of IgY buffer [100 mM 
NaH2PO4, pH 7.6, 0.02% (w/v) NaN3] and 3.5% (w/v) PEG 6 000 being subsequently added 
and dissolved with stirring. The resulting solution was centrifuged (4 420 g, 30 min, RT), and 
the supernatant filtered through adsorbent cotton wool. The final PEG concentration was 
increased to 12% (w/v) by the addition of 8.5% (w/v) PEG 6 000 and was once again dissolved 
by stirring. The mixture was pelleted by centrifugation (12 000 g, 10 min, RT), then the pellet 
was dissolved in IgY buffer equal to the yolk volume. Next, 12% (w/v) PEG 6 000 was stirred 
into the solution until it dissolved. The mixture was once again pelleted by centrifugation 
(12 000 g, 10 min, RT) and then the pellet was dissolved in a final IgY buffer [100 mM 
NaH2PO4, 0.1% (w/v) NaN3, pH 7.6] equal to sixth of the yolk volume then stored at 4oC. The 
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isolated IgY concentration was spectrophotometrically determined at 280 nm using the 
𝐸280 𝑛𝑚
1 𝑚𝑔/𝑚𝑙
= 1.25 extinction coefficient (Goldring et al., 2005). 
2.2.9.2 ELISA evaluation of antibody production 
The progress of IgY antibody production by chickens during the immunisation period against 
FLTviCATLC25A recombinant protein was monitored by ELISA. The Nunc-ImmunoTM Maxisorp 
ELISA plate wells were coated with 150 µl of rFLTviCATLC25A-PBS solution (1 µg/ml 
rFLTviCATLC25A, 100 mM NaCl, 100 mM NaH2PO4, 100 mM Na2HPO4, pH 7.4) per well for 16 
h at 4oC. The coating solution was discarded, then 200 µl blocking buffer [0.5% (w/v) BSA-
PBS, 0.1% (v/v) Tween-20] was added to each well to prevent non-specific binding of 
antibodies, then incubated at 37oC for 1 h. The wells were washed three times with 0.1% (v/v) 
Tween-20-PBS using the BIOTEK® ELx50TM microplate washer and were then incubated with 
100 µl per well of 100 µg/ml of anti-FLTviCATLC25A IgY primary antibody diluted in blocking 
buffer for 2 h at 37oC. The wells were washed again as before then 100 µl of rabbit anti-chicken 
IgY HRPO conjugate diluted 1:15 000 in blocking buffer was added to each well and incubated 
at 37oC for 1 h. The wells were washed as before and 145 µl of ABTS solution [0.15 M citrate-
phosphate buffer, 0.05% (w/v) ABTS, 0.0015% (v/v) H2O2, pH 5.0] was subsequently added 
to each well. The plate was incubated in the dark for 15 min prior to reading the absorbance 
at 405 nm using the VersaMax plate reader in 15 ml intervals until absorbance values of above 
1.0 were obtained. 
2.2.9.3 Culture and western blot of bloodstream form Trypanosoma congolense (strain 
IL 3000) parasites 
The in vitro culture of both T. congolense and T. b. brucei bloodstream form parasites were 
performed according to Eyford et al. (2011). Briefly, 10 ml Eagle’s minimum essential medium 
[EMEM base powder, 2 mM glutamine, 10 mM proline, 20% (v/v) heat-inactivated foetal bovine 
serum] was used to culture both T. congolense and T. b. brucei bloodstream form parasites 
at 27oC and 5% (v/v) CO2 until the culture became slightly overgrown. 
Cultured bloodstream form parasites were pelleted by centrifugation (2 000 g, 10 min, RT), 
washed twice with PBS (2.7 mM KCl, 2 mM KH2PO4, 137 NaCl, 100 mM Na2HPO4, pH 7.4) 
and were subsequently resuspended in 50 µl of lysis buffer [10 µM, E64, 10 mM Na2EDTA, 
1% (v/v) Triton X-100, 20 mM Tris-Cl buffer, pH 7.2]. An equal volume of reducing treatment 
buffer was added to the parasites before boiling for 10 min. A total of approximately 1 x 105 
parasites were added to each lane (20 µl) and electrophoresed on a 12.5% reducing SDS-
PAGE gel (Laemmli, 1970). The trypanosomal lysate from the SDS-PAGE gel was transferred 
onto a nitrocellulose membrane using the semi-dry blotter (Sigma) and the western blot 
performed as per Section 2.2.8.  
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2.3 Results 
2.3.1 Sub-cloning of the FLTviCATLC25A gene into the bacterial pET32-a expression 
vector 
The isolated plasmid DNA deriving from the FLTviCATLC25A-pTZ57R JM109 glycerol stocks 
were subjected to a small-scale restriction enzyme digest with EcoRI and NotI to obtain the 
gene insert for subsequent ligation into an expression vector. As shown in Figure 2.4 after 
restriction digestion two bands were produced at ±1 300 bp and ±3 000 bp which corresponds 
to the FLTviCATLC25A insert and the pTZ57R cloning vector respectively. The restriction 
digestion mixture was subsequently electrophoresed on a crystal violet containing agarose 
gel, and the 1 300 bp FLTviCATLC25A insert was excised and purified. 
 
  
 
 
 
 
Figure 2.4: Analysis of the FLTviCATLC25A insert after restriction digestion with EcoRI and NotI 
of the recombinant FLTviCATLC25A-pTZ57R clones. Lane 1, undigested FLTviCATLC25A-pTZ57R 
cloning vector. Lane 2, double digested FLTviCATLC25A-pTZ57R. Samples were electrophoresed on a 
1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide. M: O’GeneRuler. 
The purity, size and relative concentrations of the isolated FLTviCATLC25A insert along with the 
previously digested and de-phosphorylated pET32-a, pGEX4T-1 and the 2nd stock of pGEX4T-
1 (purchased separately) expression vectors were determined from Figure 2.5. Ligation 
mixtures of the FLTviCATLC25A insert with either pET32-a or pGEX4T-1 expression vectors 
were prepared which included expression vector re-ligation controls and were subsequently 
transformed into E. coli BL21 (DE3) cells by heat shock transformation. 
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Figure 2.5: Gel extraction of the FLTviCATLC25A insert after restriction digestion with EcoRI and 
NotI. The FLTviCATLC25A insert was excised from the 1% (w/v) agarose gel and purified using the 
E.Z.N.A® gel extraction kit. Samples were electrophoresed on a 1% (w/v) agarose gel containing 0.5 
µg/ml ethidium bromide. M: O’GeneRuler. 
The plasmid DNA of the resulting FLTviCATLC25A-pGEX4T-1 and FLTviCATLC25A-pET32a 
clones were isolated and first screened by performing small-scale restriction enzyme digestion 
with EcoRI and NotI (Figure 2.6). One of the two FLTviCATLC25A-pET32a colonies that were 
screened contained the ±1 300 bp insert whereas all six of the screened FLTviCATLC25A-
pGEX4T-1 colonies contained the ±1 300 bp insert.  
 
 
 
 
 
 
Figure 2.6: Restriction digest screening for recombinant FLTviCATLC25A clones ligated into 
pGEX4T-1 and pET32-a expression vectors. Following the transformation of E. coli BL21 (DE3) with 
FLTviCATLC25A-pGEX4T-1 and FLTviCATLC25A-pET-32a ligation mixtures and the selection of colonies 
for screening, the isolated plasmid from each clone was subjected to small-scale restriction enzyme 
digestion using EcoRI and NotI. Samples were electrophoresed on a 1% (w/v) agarose gel and 
visualised with 0.5 µg/ml ethidium bromide. M: O’GeneRulerTM, PC: FLTviCATLC25A-pTZ57R. 
Plasmid DNA was isolated from recombinant FLTviCATLC25A-pGEX4T-1 and FLTviCATLC25A-
pET32a and used as the template for colony PCR to amplify the 1 300 bp FLTviCATLC25A gene 
using the FLTviCATLC25A forward and reverse gene primers (Figure 2.7). An amplicon of ± 
1 300 bp was observed in each case. Different annealing temperatures were compared to 
determine which led to better amplification of the gene. 
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Figure 2.7: Colony PCR screening for recombinant FLTviCATLC25A clones ligated into the 
pGEX4T-1 and pET32-a expression vectors. Following transformation of the FLTviCATLC25A-
pGEX4T-1 and FLTviCATLC25A-pET32a ligation mixtures into E. coli BL21 (DE3) cells and selection of 
colonies, the isolated plasmid DNA from each clone was subjected to PCR amplification using the 
FLTviCATLC25A forward and reverse primers. Lanes labelled 1-3 contain FLTviCATLC25A-pGEX4T-1 
plasmids while the lanes labelled 4 contain FLTviCATLC25A-pET-32a plasmids. Samples were 
electrophoresed on a 1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide. M: O’GeneRulerTM. 
(A) Colony PCR with 64.3oC and 67oC annealing temperature. (B) Colony PCR at the 60oC annealing 
temperature. M: O’GeneRulerTM, PC: FLTviCATLC25A-pTZ57R, NC: No template DNA. 
The plasmid DNA of FLTviCATLC25A-pGEX4T-1 clones 3 and FLTviCATLC25A-pET-32a clone 
2 were sequenced using the FLTviCATLC25A forward and reverse primers for both clones as 
well as the T7 promoter and terminator primers for FLTviCATLC25A-pET32a and pGEX forward 
and reverse primers for FLTviCATLC25A-pGEX4T-1. The sequencing results showed that the 
recombinant clones all possessed the FLTviCATLC25A gene, identical to the sequence 
retrieved from GenBank® (CAEX01004850.1) apart from the intentionally introduced mutation 
(Figure A1). 
A 
B 
1 000 
3 000 
6 000 
M PC NC 1 2 3 4 M 
Ta = 60oC 
bp 
FLTviCATLC25A 
 gene 
M PC NC 1 2 3 4 PC PC NC 1 2 3 4 M 
1 000 
3 000 
1 500 
6 000 
Ta = 67oC Ta = 64.3oC 
bp 
FLTviCATLC25A 
 gene 
50 
 
2.3.2 Recombinant expression, solubilisation, refolding and purification of 
FLTviCATLC25A 
2.3.2.1 Multi-factor analysis  
The effects of three factors, i.e. expression temperature, induction duration and IPTG 
concentration were assessed based on soluble protein yield as the response measured to 
define a process with high yields and reduced time for expression of the recombinant 
FLTviCATLC25A protein in its soluble form. Soluble protein yield was measured by comparing 
the intensity of bands corresponding to FLTviCATLC25A after western blot analysis (Figure 2.8, 
B) using gel analysis software (GelAnalyzer®). To this effect, a statistical strategy based on a 
two-level full factorial screening design was performed, with two levels for each of the three 
factors (23). A sequence of eight different experimental conditions was conducted to gather 
information about these factors that may affect the soluble expression of FLTviCATLC25A. 
Results are presented in Table 2.3. 
Following expression with IPTG induction, a prominent protein band at approximately 70 kDa 
was observed for the cell lysate whereas small bands were observed at the expected size for 
the soluble fractions of the samples after staining with Coomassie blue R-250 (Figure 2.8, A).   
 
 
 
 
 
 
Figure 2.8: 12.5% Reducing SDS-PAGE and western blot analysis of multi-factor expression 
experiments of recombinant FLTviCATLC25A expression in pET32-a. Samples of the soluble 
fractions and a reference insoluble fraction sample of the multi-factor analysis of recombinant 
FLTviCATLC25A expression were electrophoresed on 12.5% reducing SDS-PAGE gels and (A) stained 
with Coomassie blue R-250 while (B) was transferred onto nitrocellulose and incubated with chicken 
anti-6xHis HRPO conjugate [1:4000 in 0.5% (w/v) BSA-PBS]. Samples are labelled according to the 
experimental set-up shown in Table 2.3. The intensity of protein bands outlined in the green boxes was 
measured using GelAnalyzer 2010a (Lazar and Lazar, 2010). M Spectra BR prestained marker. 
The results presented in the western blot analysis (Figure 2.8, B) show that the various 
changes in expression conditions didn’t lead to any meaningful production of the recombinant 
FLTviCATLC25A in the soluble form since there were no bands detected in the soluble fractions 
for any set of the tested expression conditions.  
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Table 2.3: Two-level full factorial screening design and response 
Run Expression 
temperature 
(oC) 
[IPTG] (mM) Induction 
duration (h) 
Relative soluble 
FLTviCATLC25A 
(%)  
1 37 0.1 16 0 
2 25 0.1 16 0 
3 37 1 16 0 
4 25 0.1 4 0 
5 25 1 16 0 
6 37 0.1 4 0 
7 25 0.1 4 0 
8 37 1 4 0 
 
After this screening process and observing that most, if not all, the protein was expressed in 
the insoluble fraction, it was decided that resolubilising and refolding the protein from the 
inclusion bodies would yield more protein than continuing with the optimisation experiments. 
2.3.2.2 Solubilisation, refolding and purification of recombinantly expressed 
FLTviCATLC25A 
Solubilisation of the inclusion bodies using the sarkosyl method was performed and the 
recombinantly expressed His6-tagged FLTviCATLC25A was subsequently refolded and purified 
on a nickel chelate column. Solubilisation and on-column refolding using sarkosyl resulted in 
significant amounts of homogeneous recombinant FLTviCATLC25A protein being eluted (Figure 
2.9). The purified antigen was then prepared for immunisation of chickens for antibody 
production. 
 
 
 
 
 
Figure 2.9: Nickel affinity on-column refolding and purification of solubilised recombinant 
FLTviCATLC25A using the sarkosyl method. Samples from the sarkosyl method of on-column 
refolding and nickel affinity purification was analysed on (A) 12.5% reducing SDS-PAGE stained with 
Coomassie blue R-250 and (B) western blot probed with chicken anti-His6 IgY [1:10 000]. M: 
PageRulerTM prestained marker. 
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2.3.3 Evaluation of anti-FLTviCATLC25A antibody production by ELISA 
The anti-FLTviCATLC25A IgY antibodies isolated from a single egg from each week during 
immunisation period were used for an initial ELISA to determine when the production of anti-
FLTviCATLC25A IgY antibodies peaked (Figure 2.10). Both chickens produced high amounts 
of antigen-specific IgY at weeks 6 and 10. These levels of antibody were maintained for the 
remainder of the 16 weeks during which eggs were collected. 
 
Figure 2.10: ELISA of anti-FLTviCATLC25A IgY antibodies isolated from egg yolks of immunised 
chickens. ELISA plates were coated with FLTviCATLC25A for evaluation of antibody production by the 
two immunised chickens over the 16-week period of egg collection. Antibodies (100 µg/ml) from each 
chicken were incubated and detected with rabbit anti-chicken IgG HRPO secondary antibody. The 
absorbance readings at 405 nm represent the average of duplicate experiments after 15 min 
development. Arrows indicate booster injection weeks. 
An evaluation of the titres of anti-FLTviCATLC25A antibodies (IgY purified from eggs collected 
from weeks 9-11 pooled from each chicken) showed that slightly higher titres were obtained 
for antibodies produced by chicken one compared to chicken two (Figure 2.11). Both chickens 
produced antibodies with higher titres than the pre-immune control IgY sample. 
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Figure 2.11: ELISA assessing anti-FLTviCATLC25A IgY response to recombinant FLTviCATLC25A. 
ELISA plates were coated with FLTviCATLC25A and incubated with pooled anti-FLTviCATLC25A IgY from 
each chicken at 0.1, 0.25, 0.5, 1, 2.5, 5, 10 µg/ml). Rabbit anti-chicken IgG HRPO secondary antibody 
and ABTS/H2O2 were used as the detection system. The absorbance readings at 405 nm represent the 
average of triplicate experiments after 15 min development. 
The ability of the affinity purified anti-FLTviCATLC25A IgY to recognise the corresponding 
recombinant antigen was assessed using ELISA. The affinity purified anti-FLTviCATLC25A 
antibodies showed higher absorbance values suggesting higher titres than the other antibody 
preparations: pre-immune, crude (pre-purification) and unbound (Figure 2.12). The affinity 
purified anti-FLTviCATLC25A antibodies from chicken two were then used in subsequent 
experiments to show immunological recognition of TcoCATL in T. congolense parasite lysate. 
 
Figure 2.12: Analysis of anti-FLTviCATLC25A antibodies from chicken two before and after affinity 
purification. ELISA plates were coated with FLTviCATLC25A (1 µg/ml in PBS, pH 7.4). Affinity purified (  
), crude (   ), unbound (    ), and pre-immune (    ) antibodies were diluted (0.1 – 20 µg/ml). Rabbit anti-
chicken IgG HRPO secondary antibody (1:15 000) and ABTS H2O2 were used as the detection system. 
The absorbance readings at 405 nm represent the average of duplicate experiments after 30 min 
development. 
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2.3.4 Western blot analysis of T. congolense (IL3000) parasite lysate with anti-
FLTviCATLC25A antibodies 
A western blot was performed using T. congolense (IL 3000) to determine whether the anti-
FLTviCATLC25A IgY antibodies recognise the native major CATL antigen in the bloodstream 
form of the parasite (Figure 2.13, B). The antibodies (100 µg/ml) detected the recombinant 
FLTviCATLC25A at the expected size of 70 kDa while a band corresponding to a size of 
approximately 33 kDa was detected within the parasite lysate which corresponds to that of 
native TcoCATL. 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: 12.5% reducing SDS-PAGE and Western blot analysis of bloodstream form parasite 
lysate probed by purified anti-FLTviCATLC25A IgY. The blot was incubated with anti-FLTviCATLC25A 
form chicken 2, weeks 9-11 (100 µg/ml) followed by rabbit anti-chicken IgY HRPO (1:15 000). The 
bands were developed with PierceTM ECL western blotting substrate. M: prestained protein marker. 
Lane 1, recombinant FLTviCATLC25A, lane 2, T. congolense bloodstream form lysate. (A) 12.5% 
reducing SDS-PAGE stained with Coomassie Blue R-250, (B) luminescent image of the western blot. 
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2.4 Discussion 
The diagnosis of animal African trypanosomosis is a critical aspect in the fight against the 
disease since it gives critical information that allows for the correct use of chemotherapeutics. 
New targets for chemotherapies and diagnostics need to be identified due to the process of 
antigenic variation displayed by trypanosomal parasites which hinder any progress towards a 
vaccine (Barry and McCulloch, 2001). Numerous protozoan peptidases have been identified 
as pathogenic factors and are thus targets for such studies (Mottram et al., 2004). This study 
was performed to produce a recombinant antigen that will be useful in the field diagnosis of T. 
vivax using the sera of the infected animals. The most promising technique is the serological 
ELISA technique. There are two types of serological ELISA techniques that can be used; the 
antigen-detection ELISA and the antibody-detection ELISA. For the first method, the 
recombinant antigen is used to produce antibodies that is used to detect the antigen in infected 
sera and the second would use the antigen directly to detect antibodies in infected animals. 
The expressions optimisation of the full-length inactive mutant of TviCATL (FLTviCATLC25A) 
was undertaken for possible use in diagnostics for T. vivax. The reason why an inactive form 
of the protein was used was that in a previous study of the homologous protein of T. 
Congolese, very poor yield was obtained, and the protein was unstable. Therefore, for this 
study attempts were made to improve the recombinant expression of soluble FLTviCATLC25A 
in the E. coli expression system.  
The 1.3 kb FLTviCATLC25A gene has an alanine coding sequence substituted for a cysteine 
coding sequence within the catalytic triad containing gene sequence, thus coding for an 
inactive site Ala25, His159, and Asn175 (papain numbering) as compared to active TviCATL, 
which has Cys25, His159 and Asn175 (papain numbering) in the active site (Urban et al., 2003). 
There is a wide variety of prokaryotic and eukaryotic expression systems available to produce 
recombinant proteins. Each system is associated with advantages and disadvantages; 
therefore, recombinant expression of proteins remains a matter of trial and error. Factors such 
as recombinant protein solubility, yields, stability, folding and posttranslational modifications, 
are considered when choosing an expression system for recombinant protein production 
(Rosano and Ceccarelli, 2014). The prokaryote is the first choice for recombinant expression 
of proteins (Baneyx and Mujacic, 2004).  
E. coli remains the most popular cell host for recombinant protein production,  mainly because 
when compared to other expression host organisms it offers many advantages such as fast 
growth in relatively cheap media and simple process scale-up (Rosano and Ceccarelli, 2014). 
However, for eukaryotic proteins, the lack of post-translational modifying machinery and the 
almost inevitable production of inactive protein due to the formation of inclusion bodies, offers 
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a significant challenge in this expression system (Sahdev et al., 2008). Multiple approaches 
have been devised to counteract these issues, converting inactive protein, expressed in 
inclusion bodies, into soluble and active protein. Basically, these approaches can be divided 
into three categories namely; (I) influential expression factors are modified which control the 
cellular machinery; (II) insolubly expressed protein is resolubilised; (III) and the expression of 
recombinant protein with a fusion tag/protein or chaperone (Sahdev et al., 2008). 
The first papain-like peptidase to be expressed in an E. coli system containing a T7 promoter 
was a human cysteine peptidase, cathepsin L, for which expression levels were very low, and 
the protein was produced in inclusion bodies (Smith and Gottesman, 1989). An attempt to 
express TcoCATL in E. coli was unsuccessful as it yielded incorrectly folded and inactive 
enzyme (Authié et al., 2001). However, expression of an active enzyme at marginal yields was 
achieved through a more expensive and complex Baculovirus expression system (Authié et 
al., 2001). The inactive mutant of TviCATL was previously expressed in inclusion bodies by 
(Vather, 2010), furthermore, not enough protein was expressed to sufficiently produce 
antibodies through chicken immunisation.  
The soluble recombinant expression optimisation of FLTviCATLC25A in the E. coli bacterial 
system was thus attempted for this project. There is evidence of successful expression of 
CATLs in bacteria such as; full-length TcrCATL, and to a lesser extent, the target protein of 
this project FLTviCATLC25A was previously expressed in E. coli (Vather, 2010). Subsequently, 
the FLTviCATLC25A-pTZ57R cloning vector used to obtain the FLTviCATLC25A gene was 
sourced from Vather’s (2010) work. The FLTviCATLC25A DNA insert was sub-cloned into 
pET32-a and pGEX4T-1 expression vectors using the EcoRI and NotI restriction sites. The 
FLTviCATLC25A-pET32-a and FLTviCATLC25A-pGEX4T-1 plasmid DNA was then transformed 
into chemically competent BL21 (DE3) cells before expression. The BL21 (DE3) strain was 
chosen due to it containing the T7 RNA polymerase (under the transcriptional control of a 
lacUV5 promoter, IPTG inducible) and the DE3 lysogen that renders the strain peptidase 
deficient (pET Expression System Manual).  
Recombinant expression analysis of soluble FLTviCATLC25A was undertaken using statistical 
experimental design methodology. The statistical experimental design methodology, where 
the response is evaluated by changing more than one factor at a time, allows for the 
determination of the factors that are statistically significant, considering the interactions 
between them. This multi-factor approach allows for a more thorough analysis compared to 
the widely used and traditional one factor at a time approach, where the response is evaluated 
by changing one factor at a time while fixing the others. The multi-factor analysis enables the 
characterisation of experimental error, to compare the effects of factors between themselves 
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when factors are normalised, and hence, to gather high-quality information with as few 
experiments as possible. All these advantages make this approach a powerful tool to optimise 
conditions for recombinant protein expression (Larentis et al., 2011). 
Three factors were chosen for the analysis of soluble protein expression, namely, induction 
temperature, and induction duration and inducer concentration. Besides the choice of the 
expression system itself, these factors generally have the most critical impact on the yield of 
the soluble protein upon recombinant expression. Earlier observations suggest that induction 
conditions are essential factors since they affect the ratio of soluble and insoluble protein forms 
upon recombinant expression (Rosano and Ceccarelli, 2014). Most likely the influence of 
induction conditions is related to modulation of the E. coli cells chaperone activity or other 
protein synthesis machinery involved in protein folding. Induction conditions also play a crucial 
role in protein production since low inducer concentration may be insufficient for full induction, 
whereas a high concentration of the inducer may affect the growth of the cell, especially in the 
case of production of toxic proteins (Vasina and Baneyx, 1997). Moreover, excessive induction 
time may cause noticeable degradation of the expressed recombinant protein. For a thorough 
exploration of factors of importance, it was decided that the application of a full factorial design 
should be applied. This approach is used when two or more factors are varied simultaneously 
and allows reducing the total number of experiments very considerably when compared to one 
factor at a time analysis (for the same output of data). Therefore, the three factors that were 
chosen were tested at two levels using the matrix generated by the interactive statistical 
software Design-Expert 10. This software helps to set up an optimal experimental design with 
a minimal number of tests required to explore almost all possible combinations of the factors 
and their levels. The different expression conditions and their results are presented in Table 
2.1. The soluble protein expression was estimated by quantification of soluble protein detected 
in the western blot compared to the whole rFLTviCATLC25A E. coli cell lysate (Figure 2.8, B). 
The result presented in Figure 2.8 panel B and Table 2.3, show that the intracellular 
concentration of soluble FLTviCATLC25A remained negligible despite the varying conditions of 
expression.  
The recombinantly expressed FLTviCATLC25A was successfully resolubilised and renatured 
using a non-chaotropic (sarkosyl) method during IMAC purification. Previous attempts at on-
column refolding and purification using the chaotropic (urea) method failed (Vather, 2010). 
The sarkosyl method of resolubilisation and refolding was adapted from (Schlager et al., 
2012). In this method, inclusion bodies were solubilised by SDS, the excess of which was 
precipitated using cloud point extraction by cooling and was removed from the solubilised 
protein by centrifugation. Cloud point extraction is a conventional technique used in the 
purification of membrane proteins (Arnold and Linke, 2007). According to Burgess (2009), it 
58 
 
has been seen that most proteins refold at a pH between 8 and 8.5, but the pH at which protein 
is refolded well is at one pH unit above or below the pI of the protein. The buffers used in the 
sarkosyl method all had a pH of 7.4 which is within one unit of FLTviCATLC25A’s pI which is 7.5 
as suggested by Burgess (2009). The remaining wash and elution buffers contained a low 
concentration of sarkosyl, 0.1% (w/v), to maintain the protein’s solubility during the refolding 
procedure using IMAC. The elution of refolded and purified FLTviCATLC25A in the sarkosyl 
method was performed using 50 mM imidazole concentration (Figure 2.9). This method was 
recently used to renature another cysteine peptidase, namely TcoMCA5 (Eyssen, 2014). The 
use of the sarkosyl method of solubilisation, refolding and purification resulted in the high yield 
of purified FLTviCATLC25A. 
Production of polyclonal anti-FLTviCATLC25A was achieved using simple and efficient methods 
that have developed for chicken IgY isolation and purification Pauly et al. (2011). The anti-
FLTviCATLC25A polyclonal IgY was purified on an AminoLink® resin matrixed with recombinant 
FLTviCATLC25A antigen. Large quantities of the anti-FLTviCATLC25A IgY were produced and 
isolated with the purified antibodies showing increased specificity at lower concentration when 
compared to the unbound and crude antibody samples (Figure 2.12). Dependent on the 
immunogenicity of the antigen, high antibody-titres of up to 8.37 mg/ml can be achieved after 
only 3 – 4 boost immunisations (Amro et al., 2017).  Due to the IgY antibodies’ ability to 
recognise and bind multiple epitopes, their often used in immunohistochemistry and 
immunofluorescence studies, furthermore, they are known to stay stable for over ten years in 
preservative without losing titre (De Meulenaer and Huyghebaert, 2001). Polyclonal antibodies 
have the advantage of being produced against multiple epitopes of the antigen, increasing the 
chances of protein detection but cross-reactivity is also likely (Trier et al., 2012). Affinity 
purified anti-FLTviCATLC25A IgY identified native CATL from T. congolense bloodstream form 
lysates in a western blot. The expected size of 33 kDa, as shown in Boulange et al. (2011) 
study was detected on the nitrocellulose membrane using ECL as the detection system.  
An ideal diagnostic antigen should be expressed in the mammalian infective bloodstream form 
T. vivax. Due to lack of T. vivax bloodstream-form parasite stocks, T. congolense bloodstream 
form parasites were used to confirm the antibodies ability to detect native CATL. The 
diagnostic potential of FLTviCATLC25A still needs to be verified by making use of T. vivax lysate, 
and T. vivax infected and non-infected bovine serum samples. 
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Chapter 3: MOLECULAR CHAPERONE CO-EXPRESSION OF 
TRYPANOSOMA CONGOLENSE M1 AMINOPEPTIDASES 
3.1 Introduction 
Tsetse-transmitted trypanosomosis has been termed a notifiable disease, a disease that when 
detected should be reported to the World Organisation for Animal Health (OIE). Since the 
discovery that African trypanosomes cause AAT, research and control efforts have been 
consistent and have even picked up in recent decades (Diall et al., 2017). However, despite 
recent progress, the disease still remains a major hurdle for efficient and more cost-effective 
livestock farming in large parts of sub-Saharan Africa which still has large farming potential 
(Alsan, 2015). 
Trypanosomes have developed elegant immune evasion processes that help the parasites 
escape entire host immune responses (Stijlemans et al., 2017). These immune evasion 
processes include the expression of variant surface glycoproteins that periodically switch to 
different variant antigen types to protect themselves from the host’s immune system, a process 
known as antigenic variation (Radwanska et al., 2002). Due to antigenic variation, the 
possibility of an AAT vaccine is very remote (Pays, 2006). Thus an anti-disease strategy is 
being considered in which parasite pathogenic factors are targeted (Antoine-Moussiaux et al., 
2009). Pathogenic factors are proteins which are essential to the parasite’s survival within the 
host and are identified by studying the interaction between the parasite and mammalian host 
(Holzmuller et al., 2008). Pathogeno-proteomics have facilitated the identification of new 
potential therapeutic agents as well as diagnostic targets (Holzmuller et al., 2008). A number 
of metallopeptidases have been identified as pathogenic factors as they are responsible for a 
variety of cellular processes such as evasion of the host immune systems (Ferreira and 
Andricopulo, 2017). 
The peptidases of protozoan parasites have drawn attention as potential drug targets, 
pathogenic factors and vaccine candidates (McKerrow et al., 2006; Steverding, 2013). The 
cathepsin L-like (Boulangé et al., 2011) and cathepsin B-like peptidases (Mendoza-Palomares 
et al., 2008) of T. congolense have been studied. Interestingly, both these groups of 
peptidases are encoded by multiple genes with slight variations in sequences resulting in 
peptidases with different catalytic domains. Furthermore, both cathepsin B and L-like 
peptidases are expressed only in the bloodstream form of the parasites, making them 
attractive targets for therapeutic drugs. 
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Aminopeptidases constitute a diverse set of peptidases with essential roles in a wide range of 
cellular functions (Drinkwater et al., 2017). The enzymes catalyse the removal of amino acids 
from the N-terminus of polypeptides; the specific residues of which they show an affinity, as 
well as their structure, determine their subdivision into families. The large family of M1 
aminopeptidases (clan MA, family M1) are zinc-dependent enzymes characterised by the 
presence of two conserved, catalytic sequence motifs; a consensus zinc-binding motif 
(HEXXH-(X18)-E) and the “GXMEN” exopeptidase motif (Figure 3.1) (Osório et al., 2008; 
Barrett et al., 2012). 
Aminopeptidases have been implicated in the development and pathogenesis of parasites 
(Drinkwater et al., 2017), and they have been examined as potential anti-disease vaccines or 
chemotherapeutics for Schistosoma mansoni (Maggioli et al., 2017), T. b. brucei (Knowles, 
1993) and T. cruzi (Cadavid-Restrepo et al., 2011). However, only a small selection of M1 
aminopeptidases have been examined. The M1 aminopeptidases from Toxoplasma gondii 
(Zheng et al., 2015) and the cattle pathogen T. congolense (Pillay, Boulangé, et al., 2013) 
have both been characterised as immunogenic, but their potential as drug targets are yet to 
be fully elucidated. The only parasite M1 aminopeptidase that has been extensively evaluated 
as a potential drug target is PfA-M1 from P. falciparum, a causative agent of malaria (Harbut 
et al., 2011; Mistry et al., 2014). 
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Figure 3.1: The phylogenetic relationships between the two Trypanosoma congolense family M1 
aminopeptidases and other family M1 aminopeptidases. (A) Multiple sequence alignment of a 
section of the family M1 aminopeptidases catalytic domains. The GXMEN and HEXXH cation-binding 
motifs, specific to the M1 aminopeptidases, are boxed. Sequences were obtained from Genbank® 
(http://www.ncbi.nlm.nih.gov/genbank, accessed 5-8-2016): A. thaliana (AAX59049.1), B. Taurus 
(NP001068612.1), T. brucei (AAS67871.1), E. coli (89107782), H. sapiens (P5144), M. musculus 
(31077182), S. typhi (CAD08183.1), L. major (CA5045941). (B) The phylogenetic tree is indicating the 
relationships between full protein sequences of several M1 aminopeptidases (Pillay, Boulangé, et al., 
2013). 
Due to the promising future of parasite aminopeptidase research, producing it efficiently at a 
sufficient scale is of immense importance for meeting the needs of research and diagnostics. 
Batch cultivation has been proved to be an effective means of maximising biomass and target 
protein production (Rosano and Ceccarelli, 2014). Unfortunately, insoluble aminopeptidases 
are frequently formed due to recombinant over-expression in E. coli (Drinkwater et al., 2017). 
It is well known that the over-expression of exogenous proteins usually results in substantial 
metabolic burden to cell and insoluble inclusion body due to protein misfolding (Sahdev et al., 
2008). Molecular chaperones are a highly conserved and ubiquitous group of proteins that are 
essential in the correct folding of protein during protein biosynthesis and cell stress response 
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(Figure 3.2) (Nishihara et al., 2000). Cells naturally increase the induction of molecular 
chaperone expression when under stressful conditions to help limit the presence of misfolded 
proteins during such events (Scatena et al., 2010). Recombinant expression in general is 
usually recognised as stressful to the host cell, therefore it’s likely that misfolding of the 
recombinant protein will occur (Rosano and Ceccarelli, 2014). Subsequently, the strategy of 
recombinantly over-expressing molecular chaperones with the target recombinant protein has 
been implemented to help reduce the misfolding of the desired protein (Figure 3.2). 
 
Figure 3.2: Molecular chaperone plasmid transformation flow chart. Heat-shock transformation of 
molecular chaperone plasmid carrying chemically competent E. coli BL21 (DE3) with recombinant 
aminopeptidase plasmids. Adapted from Tong et al. (2016). 
Hsp70, Hsp60 and the ribosome-associated trigger factor are suggested to be the most 
abundant and vital molecular chaperones for de novo folding of E. coli proteins (Durante and 
Colucci, 2010). To facilitate the application of these chaperone systems in E. coli host 
recombinant protein expression, commercial plasmids such as those offered by Takara Bio 
Inc were designed to allow efficient overexpression of these molecular chaperone teams. 
These commercially available chaperone teams have been implemented successfully for the 
soluble co-expression of several recombinant protein such as, Psychrobacter sp. G cold-
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active lipase Lip-948 (Shuo-shuo et al., 2011), Thermomicrobium roseum sarcosine oxide 
(Tong et al., 2016) and human CD137 ligand (Wang et al., 2012). 
  
Figure 3.3: Molecular chaperone protein folding model in E. coli. The competition between 
chaperone interaction, folding, proteolysis and aggregation of a nascent polypeptide. Both DnaK (K) 
and GroEL (EL) process misfolded protein to either proteolysis or native conformation in an ATP-
dependent manner that is managed by the DnaJ (J)-GrpE or GroES (ES) co-chaperones, respectively. 
Trigger factor (TF) is suggested to act as a general co-translational folding catalyst (Thomas et al., 
1997). 
In the present study, two family M1 aminopeptidases of T. congolense were co-expressed with 
E. coli molecular chaperones, purified and enzymatically characterised. This information could 
contribute to further studies of these M1 type aminopeptidases as either vaccine candidates 
or drug targets. 
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3.2 Materials and Methods 
3.2.1 Materials 
Molecular biology: As outlined in section 2.2.1. M1 aminopeptidase 1 and 2 from T. 
congolense both in pET-28a sourced from Pillay’s (2013) work previously done in our 
laboratory. The chaperone co-expression vectors (pTf16, pGro7, pG-KJE8, pKJE7 and pG-
Tf2) were obtained from Takara (Kyoto, Japan). E. coli BL21 (DE3)/pTf16 and BL21 (DE3)/pG-
Tf2 strains produces trigger factor (TF) and GroEL-GroES/TF molecular chaperone teams. On 
the other hand, E. coli BL21 (DE3)/pGro7, BL21 (DE3)/pG-KJE7 and BL21 (DE3)/pG-KJE8 
produced GroEL-GroES, DnaK-DnaJ-GrpE and DnaK-DnaJ-GrpE/GroEL-GroES molecular 
chaperone teams, respectively. 
Table 3.1 Expression vector and chaperone plasmid set used for the recombinant chaperone 
co-expression of T. congolense aminopeptidases 
Plasmid Molecular 
chaperones 
Promoter Inducer Resistance 
Marker 
pET-28a - lacUV5 IPTG Kanamycin 
pGro7 GroES-GroEL araB L-Arabinose Chloramphenicol 
pKJE7 DnaK-DnaJ-
GrpE 
araB L-Arabinose Chloramphenicol 
pG-Tf2 GroES-GroEL-
TF 
Pzt1 Tetracycline Chloramphenicol 
pTf16 Trigger factor 
(TF) 
araB L-Arabinose Chloramphenicol 
pG-KJE8 DnaK-DnaJ-
GrpE GroES-
GroEL 
Pzt1 Tetracycline Chloramphenicol 
 
3.2.2 Heat shock transformation of chaperone expression vectors into competent 
aminopeptidase expressing BL21 (DE3) E. coli 
The heat shock competent BL21 (DE3)/TcoAP1-pET-28a and BL21 (DE3)/TcoAP2-pET-28a 
E. coli cells (20 µl) were each thawed on ice to which 10 ng of either pG-KJE8, pKJE7, pGro7, 
pTf16 or pG-Tf2 plasmid was added to the cells. The cells were then incubated on ice for 30 
min and heat shocked for 90 s at 42oC before being incubated on ice for 2 min. Pre-warmed 
SOC medium [2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose (80 µl)] was added to the cells and incubated at 37oC 
for 1 h, with agitation (200 RPM). The transformed cells were spread plated onto 2 x YT agar 
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plates (1% agar w/v in 2 x YT medium with 34 µg/ml kanamycin and 20 µg/ml chloramphenicol) 
and incubated overnight, at 37oC. 
3.2.3 Recombinant co-expression of aminopeptidases with molecular chaperones in E. 
coli 
Single colonies of positively identified recombinant E. coli BL21 (DE3) were used to inoculate 
10 ml of 2 x YT liquid medium containing kanamycin (34 µg/ml) and chloramphenicol (20 
µg/ml). After incubation at 37oC for 16 h with agitation, 1 ml of the 2 x YT culture was diluted 
1:100 with 99 ml of fresh 2 x YT liquid medium (containing 34 µg/ml kanamycin and 20 µg/ml 
chloramphenicol), then L-arabinose (0.5 mg/ml) and/or tetracycline (10 ng/ml) were added for 
molecular chaperone over-expression induction and grown at 37oC with 200 RPM agitation 
until an OD600 of approximately 0.7 was reached. Recombinant aminopeptidase expression 
was induced with IPTG (0.1 M) at a final concentration of 1 mM at 37oC for 4 h with agitation. 
Ampicillin (50 µg/ml) was added at the start of induction as well as after 2 h. The cells were 
then pelleted by centrifugation (5 000 g, 10 min, 4oC), the pellets were resuspended in 1% 
(v/v) Triton X-100-PBS (2 ml), lysozyme added (1 mg/ml final concentration) and incubated at 
37oC for 30 min. The cell suspension was frozen at -70oC for 1 h and subsequently thawed at 
RT. The cell suspension was then sonicated four times for 30 s each, and the cellular debris 
was subsequently pelleted from the soluble protein lysate by centrifugation (5 000 g, 10 min 
4oC). The protein lysate was then filtered through Whatman No. 1 filter paper and stored at -
20oC. 
Samples of the supernatant and the pellet were analysed by a 12.5% reducing SDS-PAGE 
gel (Laemmli, 1970) and stained with Coomassie blue R-250 (as per section 2.2.6). 
3.2.4 Refolding and purification of TcoAP1 and TcoAP2 
Sarkosyl solubilisation was performed after 4 h of induced expression at 37oC with IPTG 
(1mM). The cells were pelleted by centrifugation (5 000 g, 10 min, 4oC), and to the pellet, lysis 
buffer (PCL) [8 mM Na2HPO4, 286 mM NaCl, 1.4 mM KH2PO4, 2.6 mM KCl, 1% (w/v) SDS, 
pH 7.4, 1 mM DTT] was added. The resulting solution was sonicated (2 x 2 min) and 
subsequently incubated on ice for 30 min. The solubilised proteins were separated from the 
insoluble debris by centrifugation (10 000 g, 20 min, 4oC). Samples of the supernatant and the 
pellet were electrophoresed on a 12.5% reducing SDS-PAGE gel (Laemmli, 1970) and stained 
with Coomassie blue R-250. 
After solubilisation of both aminopeptidases by sarkosyl, the denaturant was removed using 
the HiTrap desalting Sephadex G-25 resin (5 ml) on the ÄKTApurifier® system. Removal of 
the denaturant on the G-25 resin is also a form of purification as the resin not only removes 
the sarkosyl but any other low molecular weight (< 5000 Da) impurities as well. The resin was 
66 
 
washed with 2 column volumes of MilliQTM purified dH20 and equilibrated with 5 column 
volumes of wash buffer (manual run, 5 ml/min, 0.3 MPa, RT), the solubilised aminopeptidases 
(1.5 ml) were filtered through 0.45 µM filter and injected into the system. The desalting 
procedure was performed using ÄKTApurifier® system template method “HiTrap Desalting”. 
After the run, the resin was washed with 2 column volumes 0.2 M NaOH, followed by 5 column 
MilliQTM purified dH2O and finally, 5 column volumes 20% ethanol. All reagents were prepared 
with dH2O, filtered and degassed using a vacuum degasser before use.  
Refolded protein was purified on a 5 ml HisTrap® HP column using the ÄKTApurifier® and a 
gradient of 20 mM to 500 mM imidazole elution buffer (20 mM Tris-Cl, 0,5 M NaCl, pH 8.0). 
Purified protein containing fractions were identified by SDS-PAGE analysis and synthetic 
substrate fluorometric assay. The positively validated fractions were then pooled and stored 
in 20% glycerol, ready for further investigation. 
3.2.5 Enzyme assay of TcoAP1 and TcoAP2 
An AMC calibration curve was constructed to quantify the hydrolysis of a fluorogenic peptide 
substrate by the purified recombinant TcoAP1 and TcoAP2. The AMC standards ranging from 
5 to 10 000 nM (50 µl) were incubated with 50 µl aminopeptidase assay buffer (50 mM Tris-Cl 
buffer, pH 8.0, 5 mM CaCl2) at 37oC for 10 min and the fluorescence (Ex360nm and Em460nm) 
measured using a FLUORStar Optima Spectrophotometer from BMG Labtech (Offenburg, 
Germany) (Figure 3.4). The slope of the calibration curve was used to determine the enzyme 
units. Activity was measured in arbitrary fluorescence units by subtracting any background 
activity of the purified samples against a negative control. 
Samples of the eluted fractions from the on-column refolding and purification from the sarkosyl 
refolding method (50 µl) were incubated with aminopeptidase assay buffer containing 20 µM 
H-Gly-AMC substrate (50 µl) at 37oC for 10 min. Thereafter, the fluorescence (Ex360nm and 
Em460nm) was measured using a FLUORStar Optima spectrophotometer. 
  
67 
 
 
Figure 3.4: AMC standard curve showing the relationship between fluorescence and AMC 
concentration. AMC dilutions were incubated with aminopeptidase assay buffer at 37oC and the 
fluorescence measured (Ex360nm and Em460nm). The equation of the trendline is given by y = 5.1536x 
with a correlation coefficient of 0.996. The fluorescence readings represent the average of triplicate 
experiments after 10 min development. 
3.3 Results 
3.3.1 Recombinant expression of TcoAP1 and TcoAP2 in E. coli 
Expression of TcoAP1 and TcoAP2 mediated by pET28-a gave similar expression patterns in 
E. coli BL21 (DE3). Figure 3.5 shows the 91 kDa bands of TcoAP1 and TcoAP2 expressed 
with 1 mM IPTG. The expressed proteins were found almost exclusively in the insoluble 
fraction of the cell lysate.  
 
 
 
 
 
 
Figure 3.5: 12.5% reducing SDS-PAGE gel showing the expression of TcoAP1 and TcoAP2 in E. 
coli BL21 (DE3). P: pellet (insoluble fraction) S: soluble fraction. Expression induced by addition of 1 
mM IPTG. M: protein marker. 
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3.3.2 Molecular chaperone co-expression 
Five different molecular chaperones were introduced for each target protein and co-expressed 
to improve the recombinant production of soluble aminopeptidases. The 12.5% reducing SDS-
PAGE analysis of the molecular chaperone expressing E. coli cells showed bands in the 
soluble fractions corresponding to the molecular chaperones at the expected sizes i. e. DnaK 
at ~70 kDa, GroEL at ~60 kDa, TF at ~56 kDa, DnaJ at ~40 kDa, and GrpE at ~22 kDa which 
were not in the control samples (NC) that contained TcoAP1 or TcoAP2 expressing cells alone 
in Figure 3.6 and 3.7, respectively. 
 
 
 
 
 
 
 
 
Figure 3.6: TcoAP1 and chaperone co-expression 12.5% reducing SDS-PAGE analysis. TcoAP1 
was co-expressed with several molecular chaperones then samples from the cell lysate (L) and soluble 
fraction (S) were analysed by 12.5% reducing SDS-PAGE stained with Coomassie blue R-250. M: Pre-
stained protein marker, NC: No chaperones. 
Co-expression of TcoAP1 with the molecular chaperones was analysed using 12.5% reducing 
SDS-PAGE, as shown in Figure 3.6, even with the presence of significant amounts of 
overexpressed molecular chaperones, most of TcoAP1 was found within the insoluble fraction. 
A similar co-expression profile was seen for TcoAP2, were most of the protein was still found 
in the insoluble fraction (Figure 3.7).   
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Figure 3.7: TcoAP2 and chaperone co-expression 12.5% reducing SDS-PAGE analysis. TcoAP1 
was co-expressed with several molecular chaperones then samples from the cell lysate (L) and soluble 
fraction (S) were analysed by 12.5% reducing SDS-PAGE stained with Coomassie blue R-250. M: Pre-
stained protein marker, NC: No chaperones. 
In Figure 3.8, A, another 12.5% reducing SDS-PAGE analysis of the co-expression 
experiments was performed, this time only soluble fractions of the co-expression samples 
were loaded as well as the cell lysate of TcoAP1 recombinant expression without chaperones. 
Furthermore, western blot analysis was performed to detect only the His6-tagged recombinant 
protein (Figure 3.8, B), for a more sensitive and specific analysis. In Figure 3.8, A, the 
production of soluble TcoAP1 in conjunction with the molecular chaperones was compared 
with the whole cell lysate TcoAP1 sample which was not co-expressed with the chaperones. 
The production of soluble TcoAP1 seems almost negligible when compared to the total 
TcoAP1 found in the cell lysate when viewing the 12.5% reducing SDS- PAGE gel. However, 
western blot analysis of the soluble TcoAP1 co-expression samples (Figure 3.8, B) showed a 
visible increase in soluble TcoAP1 protein expression compared to the soluble fraction of the 
TcoAP1 expression without molecular chaperones (NC). Furthermore, co-expression of 
TcoAP1 with the pKJE7 chaperones (DnaK-DnaJ-GrpE) led to the biggest improvement in 
soluble TcoAP1 expression (Figure 3.9). 
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Figure 3.8: 12.5% reducing SDS-PAGE and western blot analysis of soluble recombinant TcoAP1 
after molecular chaperone co-expression. Samples of the soluble fractions and a reference cell 
lysate sample of recombinant TcoAP1 co-expression with five different molecular chaperone teams 
were electrophoresed on 12.5% reducing SDS-PAGE gels and (A) stained with Coomassie blue R-250 
while (B) was transferred onto nitrocellulose and incubated with chicken anti-His6 HRPO conjugate 
[1:4000 in 0.5% (w/v) BSA-PBS]. M: Pre-stained protein marker. NC: No chaperones. 
 
 
 
 
 
 
 
Figure 3.9: Comparison of recombinant TcoAP1 solubility after molecular chaperone co-
expression. The amount of soluble recombinant TcoAP1 were compared according to band intensities 
of the western blot using GelAnalyzer®. NC: No chaperones. 
In Figure 3.10, Panel A, another 12.5% reducing SDS-PAGE analysis of the co-expression 
performed is shown, again with only the soluble fractions to analyse soluble recombinant 
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TcoAP2 expression, western blot analysis was also performed to detect only the His6-tagged 
recombinant protein (Figure 3.10, B). The production of soluble TcoAP2 in conjunction with 
the molecular chaperones was compared with the whole cell lysate TcoAP2 sample which 
was not co-expressed with the chaperones. The production of soluble TcoAP2 also seemed 
negligible when compared to the total TcoAP2 found in the cell lysate when viewing the 12.5% 
reducing SDS-PAGE gel (Figure 3.10, A). However, western blot analysis of the soluble 
TcoAP2 co-expression samples (Figure 3.10, B) showed, as in the case of TcoAP1, a visible 
increase in soluble TcoAP2 protein expression compared to the soluble fraction of the TcoAP2 
expression without molecular chaperones (NC). Again, co-expression of TcoAP2 with the 
pKJE7 chaperones (DnaK-DnaJ-GrpE) led to the biggest improvement in soluble TcoAP2 
expression (Figure 3.11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: 12.5% reducing SDS-PAGE and western blot analysis of soluble recombinant 
TcoAP2 after molecular chaperone co-expression. Samples of the soluble fractions and a reference 
cell lysate sample of recombinant TcoAP1 co-expression with five different molecular chaperone teams 
were electrophoresed on 12.5% reducing SDS-PAGE gels and (A) stained with Coomassie blue R-250 
while (B) was transferred onto nitrocellulose and incubated with chicken anti-His6 HRPO conjugate 
[1:4000 in 0.5% (w/v) BSA-PBS]. M: Pre-stained protein marker. NC: No chaperones.  
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Figure 3.11: Comparison of recombinant TcoAP2 solubility after molecular chaperone co-
expression. The amount of soluble recombinant TcoAP2 were compared according to band intensities 
of the western blot using GelAnalyzer®. NC: No chaperones. 
3.3.3 Solubilisation, refolding and purification of recombinant TcoAP1 and TcoAP2 
Despite improvements in soluble expression of both TcoAP1 and TcoAP2 upon co-expression 
of molecular chaperones, most of the target proteins were still found in the insoluble fraction. 
Therefore for downstream processes, it was decided that solubilising the vast amount of 
insoluble protein was the best option.  
Solubilisation of the inclusion bodies using the sarkosyl method was performed, and the 
recombinantly expressed aminopeptidases were subsequently purified on a nickel chelate 
column then refolded on a G25 HiTrap desalting column. Reducing SDS-PAGE analysis of 
the refolding and purification of TcoAP1 using the sarkosyl method is shown in Figure 3.12, 
panel A, where the eluted proteins were relatively pure being eluted in fractions 1 to 10. 
Western blot analysis confirms that the eluted protein was indeed the recombinantly 
expressed TcoAP1. In addition to the 91 kDa recombinant TcoAP1, there were three 
prominent lower molecular weight degradation products at ~70 kDa, ~60 kDa and ~50 kDa 
that were detected by anti-His6 IgY antibodies in the eluted fractions 5-10 (Figure 3.12, B). 
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Figure 3.12: Nickel affinity on-column refolding and purification of solubilised recombinant 
TcoAP1 using the sarkosyl method. Samples after refolding and from the eluted fractions after affinity 
purification were electrophoresed on two 12.5% reducing SDS-PAGE gel with one (A) stained with 
Coomassie blue R-250 and the other (B) transferred onto nitrocellulose, blocked with 5% (w/v) low fat 
milk-TBS and incubated with chicken anti-His6 IgY HRPO conjugate [1:5000 in 0.5% (w/v) BSA-PBS] 
and 4-chloro-1-naphthol-H2O2 were used as the detection system. M: Spectra BR pre-stained marker. 
Reducing SDS PAGE analysis of the refolding and purification of TcoAP2 using the sarkosyl 
method is shown in Figure 3.13, A, where the eluted proteins were relatively purified and 
eluted in fractions 1 to 10. Western blot analysis confirmed that the eluted protein was indeed 
the recombinantly expressed TcoAP2. Three other lower molecular weight bands at ~70 kDa, 
~60 kDa and 50 kDa were detected,similar to the recombinant TcoAP1 preparation, with the 
anti-His6 IgY antibodies in the eluted fractions 5-10 shown in Figure 3.13, panel B. 
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Figure 3.13: Nickel affinity on-column refolding and purification of solubilised recombinant 
TcoAP2 using the sarkosyl method. Samples from the refolded fraction and from eluted fractions 
after affinity purification were electrophoresed on two 12.5% reducing SDS-PAGE gel with one (A) 
stained with Coomassie blue R-250 and the other (B) transferred onto nitrocellulose, blocked with 5% 
(w/v) low fat milk-TBS and incubated with chicken anti-His6 IgY HRPO conjugate [1:5000 in 0.5% (w/v) 
BSA-PBS] and 4-chloro-1-naphthol H2O2 were used as the detection system. M: Spectra BR pre-stained 
marker. 
3.3.4 Enzyme assay of TcoAP1 and TcoAP2 
To test if the sarkosyl method renatured recombinant aminopeptidases were indeed in their 
active form after refolding and purification, an H-Gly-AMC substrate activity assay was 
performed. As shown in Figure 3.14, both TcoAP1 and TcoAP2 showed activity against the 
substrate. 
 
Figure 3.14: Sarkosyl solubilised, refolded and purified recombinant TcoAP1 and TcoAP2 
hydrolysis of H-Gly-AMC. Equal amounts of the on-column refolded and purified TcoAP1 and TcoAP2 
eluted after sarkosyl renaturation were incubated with aminopeptidase assay buffer containing the 
fluorogenic substrate (20 µM) at 37oC for 10 min and the resulting fluorescence was measured at 
Ex360nm and Em460nm. The fluorescence readings represent the average of triplicate experiments and 
are plotted as arbitrary fluorescence units. 
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3.4 Discussion 
The need for co-ordinated actions against AAT have been recognised and therefore, in the 
last decade there has been renewed enthusiasm by governments, charities and 
philanthropists in funding research to tackle this huge challenge (Holt et al., 2016). Effective 
treatment of AAT requires a reliable and inexpensive diagnosis of the disease. Diagnosis is 
complicated due to trypanosomosis being caused by several species of trypanosomes that 
can infect several different host organisms leading to various parasite-host relationships. This 
results in most diagnostic tests having their own unique limitations that define their efficiency 
for a certain trypanosome-specific disease and therefore may need to be used in combination 
with each other in a rather scatter gun approach to diagnosis (Büscher, 2014).  
T. congolense is a vector-transmitted parasite and is present in a vast reservoir of wildlife 
animals, control of the geographic spread of the disease in sub-Saharan Africa requires 
intense surveillance and treatment programs. Control of nagana relies on accurate diagnosis 
followed by chemotherapy. A main factor that hinders the control of the disease is the lack of 
easy-to-use field appropriate diagnostics that can be used followed by rapid response for 
infection treatment. Immunoassays based on the detection of trypanosome-specific antibodies 
have relied on the use of whole trypanosome lysates as antigens, which leads to problems of 
antigen stability, test reproducibility, and lack of specificity due to the persistence of antibody 
following treatment (Büscher, 2014).  
Antigenic variation is a hurdle to the development of a standard vaccine for AAT. 
Consequently, the concept of an anti-disease vaccine, in which the pathogenic factors of the 
parasite are targeted rather than the parasite itself, has been planned (Antoine-Moussiaux et 
al., 2009). The M1 aminopeptidases of T. congolense have been identified as possible 
pathogenic factors (section 3.2.2.2), that is, parasite antigens responsible for the development 
of disease in the host. Although several aminopeptidases from parasites such as Plasmodium 
falciparum (Mistry et al., 2014) and Schistosoma mansoni (Maggioli et al., 2017) have been 
evaluated as potential vaccines or chemotherapeutics, aminopeptidases of any trypanosome 
species have only previously been investigated once by Pillay (2013). This study led to the 
insufficient yield of the recombinant T. congolense M1 aminopeptidases required for efficient 
downstream processes. For these reasons, this study was conducted to improve the soluble 
recombinant expression of the two M1 type aminopeptidases TcoAP1 and TcoAP2 from T. 
congolense. 
In Pillay’s (2013) study, TcoAP1 and TcoAP2 were cloned, sequenced and expressed as 
inclusion bodies in E. coli. Originally, recombinant expression of TcoAP1 and TcoAP2 were 
attempted in the eukaryotic system, Pichia pastoris, because both aminopeptidases have a 
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high number of predicted disufide bridges and were likely to undergo post-translational 
modifications similar to that of the native proteins resulting in soluble expressed functional 
proteins (Cereghino et al., 2002). However, even after investigating several expression 
conditions using P. pastoris, no recombinant protein was produced. Subsequently, 
recombinant expression was conducted in E. coli BL21 (DE3), and as predicted, the 
recombinant proteins were expressed in inclusion bodies even when fused with solubility 
enhancing protein fusion tags such as GST and Trx. E. coli mutants such as BL21 (DE3) that 
are deficient in ATP- dependent proteases, i.e. Lon and OmpT deficient, are regularly used to 
improve the expression of unstable recombinant proteins such as aminopeptidases. However, 
the use of these types of E. coli often results in misfolding and aggregation of the non-native 
proteins after escaping degradation. This is partly due to the accumulation of misfolded 
recombinant protein saturating the limited amount of molecular chaperones normally available 
for correct protein folding (Nishihara et al., 1998).  
The number of aminopeptidase genes which were cloned recombinantly expressed and 
biochemically characterised is progressively increasing (Drinkwater et al., 2017). However, 
high-level recombinant expression of aminopeptidases in E. coli typically results in misfolding 
and insoluble aggregation (Munkhjargal et al., 2016; Maggioli et al., 2017). The recombinant 
plasmids TcoAP1-pET-28a and TcoAP2-pET-28a were obtained from the lab. In this study, 
both 12.5% reducing SDS-PAGE and western blot analysis showed that after recombinant 
expression induction for 4 h at 37oC, both TcoAP1 and TcoAP2 were almost entirely present 
in inclusion bodies (Figure 3.5). In this study, these antigens were expressed under various 
conditions, but they were persistently produced in an insoluble form (data not shown). 
Aggregation of protein in inclusion bodies is caused by misfolding of overexpressed proteins 
which is a common occurrence in protein characterisation research (Rosano and Ceccarelli, 
2014). An increasingly popular approach for the prevention of insoluble aggregation of proteins 
is co-expression with molecular chaperones; this was employed to produce soluble 
aminopeptidases in this study. Several investigations have elucidated the mechanisms of in 
vivo protein folding and it has been shown that molecular chaperones play crucial roles in this 
process (Mogk et al., 2002). The E. coli cytoplasm is known to have three prominent molecular 
chaperone systems: Hsp60, Hsp70 and trigger factor (Baneyx and Mujacic, 2004). Upon 
leaving the exit tunnel of the ribosome newly biosynthesised polypeptides in E. coli initially 
associate with the chaperone trigger factor to prepare the nascent polypeptide to either 
spontaneously fold to its native conformation or for further folding assistance by other 
downstream chaperones (Hoffmann et al., 2010). DnaK-DnaJ-GrpE disrupts inclusion body 
build-up by binding the misfolded protein intermediates for refolding or proteolysis, thus 
reducing aggregation, while GroES-GroEL encloses misfolded protein, preventing 
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aggregation and folding the protein to native state if possible or else it promotes proteolysis 
(Kerner et al., 2005). 
The molecular chaperones used in this study were sourced from Takara Bio Inc (Kyoto, 
Japan). The product consists of a set of five plasmids that encode for the overexpression of 
five molecular chaperone teams respectively (Table 3.1). The plasmids were designed to allow 
efficient recombinant expression of these chaperones which are recognised to work together 
in the protein folding process (Nishihara et al., 1998). In a previous recombinant molecular 
chaperone co-expression study, 26 of the 50 various recombinant proteins of differing 
characteristics were shown to have improved solublity when co-expressed with differing 
combinations of the two major molecular chaperone teams, namely, GroEL-GroES and DnaK-
DnaJ-GrpE (de Marco et al., 2007). Normally these proteins form inclusion bodies when 
overproduced recombinantly in E. coli host (Dümmler et al., 2005). 
 In this study, the soluble expression levels of recombinant TcoAP1 were increased when co-
expressed with the pKJE7 (DnaK-DnaJ-GrpE), pG-KJE8 (DnaK-DnaJ-GrpE + GroES-GroEL), 
pTf16 (trigger factor), and pG-Tf2 (GroES-GroEL + trigger factor) chaperone teams while a 
decrease in solubility was observed when co-expressed with pGro7 (Figure 3.8, B). For 
TcoAP2 a similar pattern was observed with solubility of the recombinant protein increasing 
when co-expressed with the pG-KJE8, pKJE7, pTf16, pG-Tf2 chaperone teams while once 
more a decrease in solubility was observed upon co-expression with pGro7 (Figure 3.10, B).  
The general improvement in TcoAP1 and TcoAP2 recombinant soluble expression when co-
expressed with molecular chaperones could be attributed to the ability of the overexpressed 
molecular chaperone systems to refold, in vivo, large amounts of the overexpressed and 
misfolded antigens that occurred during co-expression. It could be inferred that normal 
expression induction of the molecular chaperones were insufficient to reduce the amount of 
misfolded overexpressed recombinant aminopeptidases as compared to co-expression with 
the overexpressed variant of the chaperone systems. The DnaK-DnaJ-GrpE molecular 
chaperone team’s better performance relative to the other molecular chaperone combinations 
without DnaK-DnaJ-GrpE, could be attributed to the molecular chaperones’ preference to bind 
to protein substrates larger than 60 kDa (Deuerling et al., 2003) whereas GroEL-GroES 
preferentially binds to protein substrates within the size range of 10-55 kDa due to the 
assembled GroEL-GroES complex cavity being approximately 57 kDa (Sakikawa et al., 1999). 
Furthermore, the observed decrease in soluble levels of the recombinant aminopeptidases 
when co-expressed with GroEL-GroES can be attributed to the chaperones involvement in 
promoting proteolysis. GroEL-GroES has been shown to be involved in promoting proteolysis 
during heat shock of endogenous protein aggregates in E. coli (Kędzierska et al., 1999). The 
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trigger factor molecular chaperones’ effect on the recombinant aminopeptidases solubility 
wasn’t as marked as DnaK-DnaJ-GrpE probably because trigger factor is known to be a cold 
shock chaperone and performs better at low temperatures (Piao et al., 2016), while, the co-
expression experiments in this study were done at 37oC. In de Marco et al. (2007) study, 
recombinant sucrose synthases Susy and Mash from Zea mays that were of similar size to 
the TcoAP’s showed at least three-fold improvement in solubility when co-expressed with 
molecular chaperone combinations containing DnaK-DnaJ-GrpE.  
In this study, recombinant TcoAP1 and TcoAP2 soluble expression was improved by at least 
two-fold when co-expressed with DnaK-DnaJ-GrpE (pKJE7), this was the largest improvement 
observed between the different co-expression experiments. The proposed model of this 
molecular chaperones’ protein folding process is shown in Figure 3.15. 
 
Figure 3.15: Model of the protein folding process of the DnaK-DnaJ-GrpE system (Hsp70). The 
misfolded protein (closed dot) associates with DnaJ (J), then the protein is passed to the ATP form of 
DnaK (K). This pass-over is facilitated by ATP hydrolysis. After protein transfer, DnaJ is released from 
the complex, and GrpE (E) binds to the complex triggering ADP dissociation from DnaK. This facilitates 
the binding of ATP which results in the dissociation of GrpE and folded protein from DnaK. (Bukau and 
Horwich, 1998). 
Although co-expression with the various molecular chaperone teams led to the improved 
soluble expression of the aminopeptidases, when testing these co-expressed 
aminopeptidases for correct folding via enzymatic activity assays none of them showed activity 
after 30 min incubation with known synthetic fluorometric substrate H-Gly-AMC (data not 
shown). Furthermore, most of the recombinant antigens were still found in the insoluble 
fractions of the analysed samples. Although DnaK-DnaJ-GrpE improved the solubility of both 
recombinant aminopeptidases, the recombinant antigens’ quality was probably compromised 
J 
J 
E 
Misfolded protein 
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since this molecular chaperone team is known to increase soluble aggregation of partially 
folded intermediates (Haacke et al., 2009). Hence the observation of no enzyme activity even 
after improved soluble expression levels after co-expression. The occurrence of such side 
effects in molecular chaperone co-expression indicates that strategies need to be developed 
considering that both protein solubility and conformational quality are not necessarily linked 
(Martínez-Alonso et al., 2010). Therefore, moving forward, the resolubilisation, refolding and 
purification of insoluble protein samples were performed. 
It is possible for inclusion bodies to contain protein that is close enough to native conformation 
and therefore easy to solubilise using non-ionic detergents or low concentrations of sodium 
chloride (Burgess, 2009). However, this is rarely the case as the difficulty of solubilising 
recombinant TcoAP1 and TcoAP2 inclusion bodies in guanidine was demonstrated in Pillay 
et al’s (2013) study. Therefore, in this study, a different non-ionic detergent, namely sarkosyl, 
was used for this purpose. Given the high number of cysteine residues in both APs, a reducing 
agent (DTT) was added to the inclusion body solubilisation buffer (but excluded from the 
refolding buffer) in order to minimise the incorrect formation of disulfide bonds as 
recommended by Burgess (2009). Following solubilisation of the inclusion bodies, on-column 
refolding was performed using the G25 HiTrap desalting column. The wash and elution buffers 
contained low concentrations of sarkosyl, 0.1% (w/v), to maintain the antigens’ solubility during 
the refolding procedure using both IMAC and the desalting column. The use of the sarkosyl 
method resulted in a moderately improved yield of pure aminopeptidases when compared to 
the only previous study of them. Enzyme activity assays using the H-Gly-AMC synthetic 
substrate were performed with the purified and refolded aminopeptidases, and correct folding 
was confirmed (Figure 3.14). 
Both molecular chaperone co-expression and sarkosyl resolubilisation methods were 
performed to mediate the recovery of soluble recombinant aminopeptidases from insoluble 
aggregates and showed relative improvement in recombinant antigen solubility in this study 
when compared to the only previous recombinant expression study of the T. congolense 
aminopeptidases. 
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Chapter 4: GENERAL DISCUSSION 
Animal African trypanosomosis (AAT), a neglected tropical disease, is endemic to 
approximately 70% of the countries on the African continent. The disease is estimated to have 
a yearly financial impact of between US $ 1.5 to 5 billion (Leigh et al., 2015). The debilitating 
disease caused by trypanosome parasites is mainly spread by the infected tsetse fly 
(Matthews et al., 2015). These parasites’ ability to vary their surface coats through an activity 
known as antigenic variation hugely deters the development of a vaccine (Morrison et al., 
2009). Consequently, the popular remedial approaches for AAT are targeting the tsetse-fly or 
using trypanocidal drugs. The establishment of diagnostic tests for use in cattle-herding areas 
is critical for successful treatment by allowing the proper administration of the available 
trypanocides (Giordani et al., 2016). 
Trypanosomosis diagnostics are developed to either detect the whole parasite or its 
components (mainly protein antigens, DNA or induced antibodies). Antigen detection allows 
for diagnosis of current infections, whereas antibody detection generally cannot determine if 
an infection is current or was recently cured since antibodies can persist in the bloodstream 
after cure. The gold standard microhaematocrit centrifugation is a parasite detection method 
that is simple to use. However, sensitivity is low (Masake et al., 1995) in comparison to 
molecular techniques such as loop mediated isothermal amplification (LAMP) or PCR 
techniques that need relatively complex equipment and expertise (Mitashi et al., 2012). 
Sandwich ELISA, also known as capture or antigen ELISA, is applicable for high-throughput 
screening and uses relatively inexpensive equipment when compared to PCR, but currently, 
no eligible antigen targets have been identified, despite several investigations (OIE, 2013). 
Antibody detection was originally done by indirect fluorescence antibody test (IFAT) or 
parasites fixed on a slide (Katende et al., 1987). Other forms of antibody detection techniques 
include the use of indirect ELISA that is most popular for antibody detection in sera diagnosis. 
The use of whole parasite lysates as a source of antigen is a major limitation to these 
techniques because it is difficult to standardise trypanosome lysates. These lysates are 
prepared in different ways either from parasites propagated in rodents or grown in culture 
using different protocols. Additionally growing T. vivax in culture is particularly difficult 
(Boulangé et al., 2017). Furthermore, because of the high-level homology between the 
salivaria group of trypanosomes, species-specific diagnosis remains elusive, although not 
impossible, with this issue marginally resolved by analysing cross-reactions between species 
(Hopkins et al., 1998).  
These hurdles can be overcome by using purified recombinant antigens previously identified 
as pathogenic factors, instead of whole parasite lysates, because antigen production can be 
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standardised resulting in improved species-specific diagnosis. However, this approach 
requires relatively expensive and complex equipment, and expertise which reserves this 
approach for extensive epidemiological studies rather than point-of-care decisions in the field 
performed by the farmers (Boulangé et al., 2017). An optimised ELISA test can be converted 
to an immunochromatographic or rapid diagnostic test (RDT) or “dipstick” format for use under 
field conditions, perfect for end-users. The Surra Sero K-SeT antibody RDT based on 
recombinant variant surface glycoprotein rVSG RoTat 1.2 was developed for T. evansi 
diagnosis and is commercially available (Birhanu et al., 2015). Further RDTs based on T. 
congolense cathepsin B and T. vivax GM6 antigen, a flagellar tandem repeat protein, showed 
much promise for field diagnosis (Boulangé et al., 2017). 
Over time more antigens with diagnostic potential for trypanosomosis have been identified 
and produced, using optimisable and standardised recombinant technology, to avoid the use 
of unstable native parasite antigens for diagnosis. The ideal trypanosome antigens with 
diagnostic potential are immunodominant antigens found in the bloodstream development 
stage of the parasite (Thuy et al., 2012). Trypanosome cysteine peptidases are considered as 
immunodominant antigens with potential for the development of AAT serodiagnostic tools 
(Lalmanach et al., 2002). In addition to the cysteine peptidases, the family M1 
aminopeptidases were also identified as potential pathogenic factors (Pillay, Boulangé, et al., 
2013). However, a recurring theme that is revealed in recombinant expression studies of these 
antigens is the production of the desired antigen within inclusion bodies due to misfolding and 
aggregation. Soluble recombinant expression of these antigens, in high enough yields and 
correct conformation, is required for downstream processes such as antibody production and 
functional characterisation. 
The aim of this research project was to optimise the soluble recombinant expression of the 
previously studied and potential diagnostic targets, full-length mutant TviCATL from T. vivax  
FLTviCATLC25A (Vather, 2010) and the two T. congolense family M1 aminopeptidases TcoAP1 
and TcoAP2 (Pillay, Boulangé, et al., 2013). Recombinant protein expression in E. coli has 
developed over the years to produce high amounts of soluble target when compared to other 
methods of obtaining target protein (Rosano and Ceccarelli, 2014).  
The first papain-like peptidase to be expressed in an E. coli expression system containing a 
T7 promoter was human cathepsin L. The recombinant expression levels of protein obtained 
in that study were very low and the resultant protein was mostly expressed in an inactive form 
within inclusion bodies (Smith and Gottesman, 1989). Early attempts to express TcoCATL 
from T. congolense in E. coli was unsuccessful as this yielded misfolded, inactive protein 
(Boulangé et al., 2001). However, a later expression study produced a marginal increase in 
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yields and the production of active enzyme using the much more expensive and complicated 
baculovirus expression system (Boulangé et al., 2001). A CATL-like peptidase from 
Leishmania braziliensis was also expressed in E. coli mostly in inclusion bodies where 
resolubilisation and on-column refolding were used to recover an active enzyme (Lanfranco 
et al., 2008). 
The FLTviCATLC25A construct used in the present study is an inactive mutant of TviCATL and 
was investigated for its potential as a diagnostic target (Vather, 2010). TviCATL belongs to 
Clan CA of the CP family and has a classical papain-like catalytic triad of Cys25, His159 and 
Asn175 (papain numbering), however, this mutant construct had Cys25 replaced by Ala25 by 
Vather et al (2010). The mutant construct contains a pro-peptide domain (120 residues), which 
is auto-catalytically cleaved at acidic pH in the case of active constructs (Jackson, 2011), a 
catalytic domain connected to a C-terminal domain by a poly-proline hinge region and Trx 
fusion tag from the pET32-a expression vector which reportedly improves solubility of 
recombinant proteins (Young et al., 2012). The C-terminal region is unique to parasite cysteine 
peptidases and is completely absent in the mammalian homologues (Mottram et al., 2004). 
The function of the C-terminal region is currently speculative, however, it has been 
hypothesised that it may play a role in targeting the enzyme to the lysosome or glycosome, as 
is the case for the phosphoglycerate kinase of Crithidia fasciculata (Swinkels et al., 1988). 
Moreover, the presence of an N-glycosylation site in this region could potentially allow 
attachment of a lysosome targeting marker. 
The recombinant expression of FLTviCATLC25A, TcoAP1 and TcoAP2 using the standard 
cultivation conditions established in our laboratory led to the recombinant antigens being 
produced almost entirely in inclusion bodies. Inclusion bodies are composed predominantly of 
the recombinant protein with contaminating proteins representing less than 15% of the 
inclusion body (Ramón et al., 2014). Various factors may contribute to inclusion body 
formation including: very high concentration of the recombinant protein within the cytosol 
leading to insoluble protein aggregation, inadequate amounts of endogenous molecular 
chaperones resulting in promotion of hydrophobic interactions between partially folded 
polypeptides, inhibition of disulfide linkage formation since the E. coli cytosol is in a reducing 
state and a lack of the post-translational modifying cellular machinery thus producing less 
stable eukaryotic recombinant protein (Walsh, 2002). Recombinant proteins within inclusion 
bodies are predominantly composed of partially folded protein intermediates that are 
consequently biologically inactive (Walsh, 2002). Hence, to obtain these recombinant antigens 
for effective downstream processing, inclusion body formation must be avoided. If this is not 
possible then the soluble recombinant antigens must be recovered from the inclusion bodies.   
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For the optimisation of FLTviCATLC25A soluble recombinant protein expression, the BL21 
(DE3) E. coli strain was chosen. This strain of E. coli is deficient in the Lon and OmpT 
proteases with the former responsible for degrading foreign proteins while the latter is an outer 
membrane protease that degrades extracellular proteins (Daegelen et al., 2009). These 
modifications help prevent the digestion of recombinant protein after cell lysis. Cultivation of 
E. coli for recombinant protein expression is usually done with a set of techniques that are in 
combination known as batch cultivation (Sørensen and Mortensen, 2005). Batch cultivation is 
a relatively easy and inexpensive approach to achieving high-density E. coli cultures. In 
various protein expression experiments, achieving an OD600nm of 0.8 (approximately 6.4 x 108 
cells/ml) within 4 hours is common when using “standard” cultivation conditions i.e 2 x YT 
complex medium, 37oC cultivation temperature and 200 RPM agitation. Escherichia coli 
reaches mid exponential growth phase, the preferred phase for recombinant gene expression 
(Khow and Suntrarachun, 2012), at approximately 4 h when cultivating at 37oC. The 2 x YT 
medium was used instead of the more popular LB broth because it has consistently shown to 
improve cell densities during recombinant expression when comparisons were done (Atlas, 
2015). Optimising the batch cultivation conditions is regarded as the simplest approach to 
improving soluble recombinant protein expression. 
In this study, a factorial design was implemented for optimising cultivation conditions to 
improve the soluble expression of recombinant FLTviCATLC25A. Three factors were initially 
chosen for screening, namely, cultivation temperature, inducer (IPTG) concentration and 
induction time. These factors were chosen because they are generic factors that can be 
applied to most soluble protein production studies and because these factors are known to 
have an impact on recombinant protein solubility during recombinant expression in E. coli host 
due to them primarily affecting the rate of protein biosynthesis.  Generally reducing the 
agitation rate should decrease the formation of inclusion bodies, however, this will inevitably 
decrease cell growth and total protein production (Papaneophytou and Kontopidis, 2014). 
High cultivation temperature promotes cell growth; however, high temperature can have a 
negative impact on soluble protein expression since higher growth rates lead to a higher 
likelihood of plasmid loss, increased errors during the gene expression process and inevitably 
leads to an increase in improperly synthesised recombinant protein that become misfolded 
(Mosrati et al., 1993). This is a vital issue when it comes to gene expression from expression 
vectors. In general, protein aggregation is favoured at high temperatures because 
hydrophobic interactions between protein macromolecules are promoted as the temperature 
increases (Kiefhaber et al., 1991). Taking the effects of high temperature in consideration, it 
is evident that decreasing temperature usually has a beneficial impact on improving solubility 
of recombinant protein. Decreased temperature, coupled with increased induction duration 
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greatly benefited the soluble expression of many recombinant proteins, but arriving at the best 
combination of these two factors is generally a trial-and-error exercise (Papaneophytou and 
Kontopidis, 2014). In terms of inducer concentration, this factor has been found to affect 
recombinant protein yields. A low concentration results in inefficient protein expression 
induction, whereas excess inducer concentration can be toxic to the E. coli host, causing 
reduced cell growth and recombinant protein concentration (Ramirez et al., 1994). It has been 
previously shown that IPTG concentrations between 0 and 1 mM does not affect E. coli growth 
rate or maximum cell density, however, this depends on the combination of cell host, 
expression vector and recombinant protein used in a study. 
To screen the above-mentioned factors for their influence on recombinant FLTviCATLC25A 
solubility, a design of experiments approach called full factorial design was employed. Initially 
little information was available to determine the influence of various factors on soluble 
recombinant expression of FLTviCATLC25A, therefore examining multiple factors 
simultaneously was advisable and this approach allowed for that. Full factorial design was 
performed by using a two-level full factorial, meaning that two levels were chosen for each 
factor, namely a lower (-) and higher (+) level. For induction temperature the lower level was 
30oC and the higher level was 37oC, for induction duration 4 h and 16 h were the respective 
levels while for the inducer concentration 0 and 1 mM were tested. The three factors and their 
levels were then combined to develop a design matrix (using Design Expert® software) on 
which the factor screening experiments were based. After performing all the experiments 
based on this matrix, no observable improvement on soluble expression of rFLTviCATLC25A 
was achieved. This consequently led to the discontinuation of attempts to optimise the 
cultivation conditions for soluble expression improvement and initiated the resolubilisation 
process in attempts to recover the recombinantly expressed protein from inclusion bodies. 
Polyclonal anti-FLTviCATLC25A antibodies were produced in chickens due to the efficiency and 
simplicity of chicken IgY isolation and purification methods (Pauly et al., 2011). The anti-
FLTviCATLC25A polyclonal IgY was purified on affinity resins prepared by immobilising 
recombinant FLTviCATLC25A on the AminoLink® coupling matrix. Large quantities of the anti-
FLTviCATLC25A IgY were produced and isolated with the purified antibodies showing high 
specificity at relatively low concentrations. Parasite CATL’s are localised in lysosomes and are 
released into the host bloodstream upon parasite death and lysis (Caffrey and Steverding, 
2009), therefore the generated polyclonal antibodies were tested against the bloodstream 
form of a parasite for antigen detection. The affinity purified anti-FLTviCATLC25A IgY 
recognised native 33 kDa CATL in T. congolense bloodstream form lysates in a western blot.  
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For future work, it will be necessary to conduct antibody detection inhibition ELISA in parallel 
with an indirect antibody detection ELISA to compare the specificity, sensitivity and 
reproducibility of the diagnostic procedures. In this analysis it will be necessary to include 
Kinetoplastidae other than trypanosomes present in areas where AAT is endemic to use as 
negative controls. To further improve serodiagnosis accuracy, it would be ideal to develop an 
antigen detection ELISA (Eisler et al., 2004). The antibodies that were produced in this study 
may be the starting point for such a development, in which the detection of TviCATL antigen 
from T. vivax infected sera can be investigated. The steps for the proposed antigen detection 
ELISA are: coat with chicken anti-FLTviCATLC25A antibodies, probe with T. vivax infected sera 
from cattle and use a rabbit anti-IgY-HRPO conjugate with the appropriate chromogen for 
detection. 
The family M1 aminopeptidases are metallopeptidases requiring a divalent metal co-factor for 
the catalysis of single amino acid residues from the N-terminal end of peptides. 
Aminopeptidases have only been previously studied in T. congolense (Pillay, Boulangé, et al., 
2013)  The leucyl aminopeptidases of Fasciola hepatica and Haemonchus contortus were 
evaluated for their protective potential in conventional vaccines with some success (Acosta et 
al., 2008). Interestingly, the leucyl aminopeptidase of F. hepatica was used in conjunction with 
the primary cysteine peptidase as a cocktail vaccine. However, the best protection (89%) was 
achieved using leucyl aminopeptidase alone (Piacenza et al., 1999). Furthermore, it has been 
shown that inhibition of the M1 aminopeptidases of P. falciparum results in growth inhibition 
in vitro (Skinner-Adams et al., 2010).  
In Pillay et al. (2013) study, TcoAP1 and TcoAP2 were expressed in inclusion bodies in E. 
coli. Initially, recombinant expression of both aminopeptidases was attempted in the 
eukaryotic system, Pichia pastoris, since the aminopeptidases had a high number of predicted 
disulfide bridges and would be likely to undergo post-translational modifications similar to 
those of the native proteins resulting in soluble expressed functional proteins (Cereghino et 
al., 2002). However, even after testing several expression conditions using P. pastoris, no 
expression was achieved. Subsequently, within the same study, recombinant expression was 
conducted in E. coli BL21 (DE3), and as predicted, the recombinant proteins were expressed 
in inclusion bodies using the pGEX-4T-1 (GST fusion tag), pET28-a and pET32-a (Trx fusion 
tag) vectors (Pillay, Boulangé, et al., 2013). Several similar aminopeptidases have previously 
been expressed as soluble active proteins in E. coli including the M1 aminopeptidase of P. 
falciparum, PfAM1, the leucyl aminopeptidases of F. hepatica and those of three Leishmania 
species, all of which had fused polyhistidine tags to aid purification (Morty and Morehead, 
2002; Acosta et al., 2008; González-Bacerio et al., 2014). Similarly, the methionine 
aminopeptidase of P. falciparum, leucyl aminopeptidases of the tick Haemaphysalis 
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longicornis, the apicomplexan parasite Toxoplasma gondii and the pathogenic bacterium 
Salmonella enterica, were all expressed as soluble active enzymes using a GST fusion protein 
tag in an E. coli expression system (Mathew et al., 2000; Hatta et al., 2006; Jia et al., 2010). 
The leucyl aminopeptidases of the flukes Schistosoma mansoni and S. japonicum, were 
expressed in a different expression system namely the eukaryotic Baculovirus expression 
system (McCarthy et al., 2004). It is speculative as to why the expression of both TcoAP1 and 
TcoAP2 failed in P. pastoris (Pillay et al., 2013), but it was suggested that the active form of 
the T. congolense aminopeptidases may be toxic to the yeast, as was the case for the serine 
peptidase trypsin (Hanquier et al., 2003). Processing of the zymogen during the recombinant 
expression resulted in very low yields of the active trypsin being recovered. However, it was 
found that by preventing maturation using a single point mutation resulted in a large amount 
of the zymogen being recombinantly expressed in P. pastoris (Hanquier et al., 2003). 
In the present study, both reducing SDS-PAGE and western blot analysis showed that after 
recombinant expression induction under standard conditions (4 h incubation at 37oC), both 
TcoAP1 and TcoAP2 were almost entirely present in inclusion bodies. In this and the previous 
(Pillay, Boulangé, et al., 2013) study, these proteins were expressed under various conditions 
but were persistently produced in an insoluble form. Aggregation of protein in inclusion bodies 
is caused by misfolding of overexpressed proteins which is a common occurrence in protein 
characterisation research (Rosano and Ceccarelli, 2014). An increasingly popular approach 
for the prevention or mitigation of insoluble aggregation of proteins is co-expression with 
molecular chaperones. This approach was subsequently employed in the present study to 
produce soluble aminopeptidases. Molecular chaperones are involved in the crucial stages of 
de novo protein folding, and several studies have shed more light on the exact mechanisms 
of this process (Mogk et al., 2002). The E. coli cytoplasm is known to have three prominent 
chaperone systems, namely, Hsp60, Hsp70 and trigger factor (Baneyx and Mujacic, 2004). 
Upon leaving the ribosome’s exit channel, newly biosynthesised polypeptides in E. coli initially 
covalently interact with the chaperone trigger factor to prepare the nascent polypeptide to 
either spontaneously fold to its native conformation, or for further folding assistance by other 
downstream chaperones (Hoffmann et al., 2010). DnaK-DnaJ-GrpE (Hsp70 chaperone family) 
decreases inclusion body formation by degrading misfolded proteins, while GroEL-GroES 
(Hsp60 chaperone family) participates in the transition of protein from insoluble to soluble 
fractions and promotes disaggregation, thus limiting the formation of inclusion bodies (Kerner 
et al., 2005). The soluble expression levels of recombinant TcoAP1 were increased when co-
expressed with the pKJE7 (DnaK-DnaJ-GrpE), pG-KJE8 (DnaK-DnaJ-GrpE + GroES-GroEL), 
pTf16 (trigger factor), and pG-Tf2 (GroES-GroEL + trigger factor) chaperone teams while a 
decrease in solubility was observed when co-expressed with pGro7. For TcoAP2 a similar 
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pattern was observed with solubility of the recombinant protein increasing when co-expressed 
with the pG-KJE8, pKJE7, pTf16, pG-Tf2 chaperone teams while once more a decrease in 
solubility was observed upon co-expression with pGro7. 
The pKJE7 (DnaK-DnaJ-GrpE) chaperone team gave the largest improvement of recombinant 
soluble levels for both TcoAP1 and TcoAP2. The DnaK-DnaJ-GrpE molecular chaperone 
team performs three different tasks when it comes to interacting with protein substrates: it 
plays a part in de novo folding of protein, it refolds or degrades denatured protein and more 
importantly in the context of this study, it is involved in reversing insoluble aggregation of 
protein (Betiku, 2006). It has been suggested that it disaggregates protein by performing an 
ATP-dependent unfolding process that allows for lengthy binding of thermolabile protein 
substrate (Goloubinoff et al., 1989), therefore preventing aggregation and stabilising the 
protein substrate for refolding (Buchberger et al., 1996). The DnaK-DnaJ-GrpE molecular 
chaperone team performed better than the other chaperone teams probably because it 
preferentially binds to newly synthesised polypeptides that are larger than 60 kDa (Deuerling 
et al., 2003) whereas the GroEL-GroES chaperone team prefers to bind newly synthesised 
polypeptides that are in the size range of between 10-55 kDa (Sakikawa et al., 1999). Both 
TcoAP1 and TcoAP2 were recombinantly expressed as ~91 kDa proteins. Trigger factor is a 
cold shock molecular chaperone (Piao et al., 2016), and therefore did not perform as well as 
the DnaK-DnaJ-GrpE molecular chaperone team probably because recombinant co-
expression experiments were done at 37oC cultivation temperature.  
Although the molecular chaperone co-expression experiments markedly improved the soluble 
expression of the recombinant aminopeptidases, when compared to their previous study 
(Pillay, Boulangé, et al., 2013), most of the recombinant antigens were still found in inclusion 
bodies. As with FLTviCATLC25A, renaturation was performed on the recombinant 
aminopeptidases using the sarkosyl method adapted from Schlager et al (2012). 
All three recombinantly expressed antigens were resolubilised and renatured using the non-
chaotropic (sarkosyl) method during immobilised metal affinity chromatography (IMAC) 
purification. Previous attempts at on-column refolding and purification using the chaotropic 
(urea) method failed for FLTviCATLC25A Vather (2010), whereas Pillay et al. (2013) attempts 
at renaturing the recombinant aminopeptidases using the chaotropic agent guanidine was 
tedious and led to a large loss of the expressed antigens during this process. In the sarkosyl 
resolubilisation method, inclusion bodies were solubilised by SDS, the excess of which was 
precipitated using cloud point extraction by cooling and was removed from the solubilised 
protein by centrifugation. Cloud point extraction is a standard technique used in the purification 
of membrane proteins (Arnold and Linke, 2007). The remaining wash and elution buffers 
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contained a low concentration of sarkosyl [0.1% (w/v)] to maintain protein solubility during the 
on-column refolding procedure. This method was recently used to renature a cysteine 
peptidase, namely TcoMCA5 (Eyssen, 2014). The use of the sarkosyl method of solubilisation, 
refolding and purification resulted in much higher yields for all three recombinantly expressed 
antigens when compared to previous recombinant expression studies (Vather, 2010; Pillay, 
Boulangé, et al., 2013). 
In the present study, the active-site mutant full-length CATL from T. vivax, FLTviCATLC25A and 
the family M1 aminopeptidases of T. congolense, TcoAP1 and TcoAP2 were expressed and 
renatured using an E. coli expression system in conjunction with the sarkosyl renaturation 
method to produce high yields of homogeneous recombinant antigens that were amenable to 
their use as antigens in diagnostic tests. For future studies, it is important to continue 
improving the yields of homogenous recombinant antigen for downstream processes such as 
protein crystallisation to obtain the three-dimensional structures of these therapeutically 
important antigens. Interestingly, the design of experiments that were used in this study is a 
versatile approach that can also be used to optimise the factors involved in crystallisation trials 
such as pH, protein and PEG concentrations. Previous crystallisation condition optimisation 
for TcoCATL were attempted by Jackson (2011) and was partially successful as needle-like 
crystals were obtained, however, it may be of interest to use the design of experiments 
approach to improve outcomes. 
In conclusion, two different approaches to recombinant soluble protein expression 
optimisation were undertaken and in the instance of molecular chaperone co-expression, a 
two-fold improvement of soluble recombinant aminopeptidase expression was achieved when 
co-expressed with DnaK-DnaJ-GrpE. In the case of FLTviCATLC25A, although the design of 
experiments approach to FLTviCATLC25A expression optimisation did not improve soluble 
expression of the protein, the use of the non-chaotropic sarkosyl method for its resolubilisation 
led to much higher yields and more efficient downstream processing. This study developed 
optimised and standardised procedures for high-yield recombinant expression and purification 
of three potential diagnostic antigens, namely, the T. vivax recombinant antigen, 
FLTviCATLC25A and the T. congolense recombinant antigens TcoAP1 and TcoAP2, using the 
inexpensive and readily obtainable E. coli BL21 (DE3) expression system.  
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APPENDIX 
Figure A1: Sequence of the full-length mutant TviCATL (FLTviCATLC25A). Amino acids of the 
inactive site are highlighted in cyan, and its DNA sequence is highlighted in pink. 
         10        20        30        40        50        60        70        80        90       100                   
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CTCCAGACTTTATCGACTCACTATAGGGAAAGCTTGCATGCAGGCCTCTGCAGTCGACGGGCCCGGGATCCGATTAAAGAATTCTACATGGCGGTGCTGC  
 L  Q  T  L  S  T  H  Y  R  E  S  L  H  A  G  L  C  S  R  R  A  R  D  P  I  K  E  F  Y  M  A  V  L  
 
        110       120       130       140       150       160       170       180       190       200          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
GCGCGGAGGGGCCCGTGGAGCCGCTGTTTGCGGCGTTCAAGCAGAAGTACGGCAGGTCGTACGGGACCGCGGCGGAGGAGGCGTTCCGCCTGCGCGTATT  
R  A  E  G  P  V  E  P  L  F  A  A  F  K  Q  K  Y  G  R  S  Y  G  T  A  A  E  E  A  F  R  L  R  V  F  
 
        210       220       230       240       250       260       270       280       290       300          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CGAGGACAACATGCGCCGGTCGCGGATGTACGCGGCGGCAAACCCGCACGCGACGTTCGGTGTCACGCCGTTCTCGGACCTCACGCCCGAGGAGTTCAGG  
  E  D  N  M  R  R  S  R  M  Y  A  A  A  N  P  H  A  T  F  G  V  T  P  F  S  D  L  T  P  E  E  F  R  
 
        310       320       330       340       350       360       370       380       390       400          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ACACGCTACCACAACGGCGAGCGCCACTTCGAGGCAGCGCGGGGGCGCGTGAGGACGCTGGTGCAGGTGCCGCCGGGCAAGGCGCCCGCCGCCGTGGACT  
 T  R  Y  H  N  G  E  R  H  F  E  A  A  R  G  R  V  R  T  L  V  Q  V  P  P  G  K  A  P  A  A  V  D  
 
        410       420       430       440       450       460       470       480       490       500          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
GGCGCCGCAAGGGTGCGGTGACGCCCGTCAAGGACCAGGGCAGGTGCGGCTCCGCCTGGTCCTTCTCCGCCATTGGGAACATCGAGGGCCAGTGGGCGGC  
W  R  R  K  G  A  V  T  P  V  K  D  Q  G  R  C  G  S  A  W  S  F  S  A  I  G  N  I  E  G  Q  W  A  A  
 
        510       520       530       540       550       560       570       580       590       600          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TGCCGGCAACCCGCTGACGAGTCTGTCGGAGCAGATGCTTGTGTCGTGCGACACCACGGATAGTGGTTGCAGTGGTGGCCTGATGGACAACGCATTCGAG  
  A  G  N  P  L  T  S  L  S  E  Q  M  L  V  S  C  D  T  T  D  S  G  C  S  G  G  L  M  D  N  A  F  E  
 
        610       620       630       640       650       660       670       680       690       700          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TGGATCGTGAAGGAGAACAGTGGCAAGGTGTACACGGAGAAGAGCTATCCCTACGTCTCTGGCGGTGGCGAGGAGCCGCCCTGCAAGCCGCGTGGGCACG  
 W  I  V  K  E  N  S  G  K  V  Y  T  E  K  S  Y  P  Y  V  S  G  G  G  E  E  P  P  C  K  P  R  G  H  
 
        710       720       730       740       750       760       770       780       790       800          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AGGTCGGTGCCACGATCACCGGCCACGTGGACATCCCGCACGACGAGGACGCCATCGCCAAGTACCTCGCCGACAACGGCCCGGTCGCTGTGGCCGTGGA  
E  V  G  A  T  I  T  G  H  V  D  I  P  H  D  E  D  A  I  A  K  Y  L  A  D  N  G  P  V  A  V  A  V  D  
 
        810       820       830       840       850       860       870       880       890       900          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CGCCACCACCTTCATGTCGTACAGTGGCGGTGTGGTGACGTCCTGCACCTCCGAGGCGCTGAACCACGGCGTGCTCCTCGTCGGCTACAACGACAGCAGC  
  A  T  T  F  M  S  Y  S  G  G  V  V  T  S  C  T  S  E  A  L  N  H  G  V  L  L  V  G  Y  N  D  S  S  
 
        910       920       930       940       950       960       970       980       990       1000         
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AAGCCGCCGTACCGGATCATCAAGAACCCGTGGAGCTCGTCGTGGGGCGAGAAGGGCTACATCCGCATCGAGAAGGGCACGAATCAGTGTCTGGTGGCGC  
 K  P  P  Y  R  I  I  K  N  P  W  S  S  S  W  G  E  K  G  Y  I  R  I  E  K  G  T  N  Q  C  L  V  A  
 
        1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AGCGCGCGTCGAGTGCTGTTGTTGGTGGCCCCGGTCCCACGCCCACGCCCACGCCCACGCCAACAACAACAACAACAACGACCGCACCTGGCCCATCGTC  
Q  R  A  S  S  A  V  V  G  G  P  G  P  T  P  T  P  T  P  T  P  T  T  T  T  T  T  T  A  P  G  P  S  S  
 
        1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AAGCTTCACGAAGACGCTTTGCAGCGGTGATGATTGCGCCGACAACTGTTCAGCGACTGTCTACAACACGAACACGTGCATCCGGCTGGGCGCGCTTGGC  
  S  F  T  K  T  L  C  S  G  D  D  C  A  D  N  C  S  A  T  V  Y  N  T  N  T  C  I  R  L  G  A  L  G  
 
        1210      1220      1230      1240      1250      1260      1270      1280      1290      1300         
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TCGATGGTGGCCACGTGCGGCGCGGGGGTGCTTGAGCTGAAGGCCTACATGCAGAATGAGCAGTGCACTGGCACCCCGGAGCGGCTCAGCCTGCCGCTGG  
 S  M  V  A  T  C  G  A  G  V  L  E  L  K  A  Y  M  Q  N  E  Q  C  T  G  T  P  E  R  L  S  L  P  L  
 
        1310      1320      1330      1340      1350      1360      1370      1380             
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|. 
ACAAGTGCCTGGCGTCGCTCAGCGTGTCGGCAACGTACCACTGCAACTATGGCGCACCGGCGTAAGAACAGCGGCCGCCCCTTTGG  
D  K  C  L  A  S  L  S  V  S  A  T  Y  H  C  N  Y  G  A  P  A  *  E  Q  R  P  P  L  W  
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